{{#lst:Section editor transclusions|breast}}
<big>'''Note: these are biomarker-specific regimens, please see the [[breast cancer|main breast cancer page]] for other regimens.'''</big>
{| class="wikitable" style="float:right; margin-right: 5px;"
|-
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
|}
{{TOC limit|limit=3}}

=Guidelines=
==[http://www.asco.org/ ASCO]==
*'''2018:''' Ramakrishna et al. [http://ascopubs.org/doi/full/10.1200/JCO.2018.79.2713 Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline update] [https://www.ncbi.nlm.nih.gov/pubmed/29939840 PubMed]
*'''2018:''' Giordano et al. [http://ascopubs.org/doi/full/10.1200/JCO.2018.79.2697 Systemic therapy for patients with advanced human epidermal growth factor receptor 2–positive breast cancer: ASCO Clinical Practice Guideline update] [https://www.ncbi.nlm.nih.gov/pubmed/29939838 PubMed]
*'''2016:''' Harris et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4933134/ Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline]
*'''2015:''' Van Poznak et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478102/ Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology Clinical Practice Guideline]
===Older===
*'''2014:''' Giordano et al. [http://ascopubs.org/doi/full/10.1200/JCO.2013.54.0948 Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline] [https://www.ncbi.nlm.nih.gov/pubmed/24799465 PubMed]
*'''2014:''' Ramakrishna et al. [http://ascopubs.org/doi/full/10.1200/JCO.2013.54.0955 Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline] [https://www.ncbi.nlm.nih.gov/pubmed/24799487 PubMed]

==[http://www.esmo.org/ ESMO]==
*'''2017:''' Cardoso et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378224/ 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).] [https://www.ncbi.nlm.nih.gov/pubmed/28177437 PubMed]
*'''2015:''' Senkus et al. [http://annonc.oxfordjournals.org/content/26/suppl_5/v8.full.pdf+html Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.] [https://www.ncbi.nlm.nih.gov/pubmed/26314782 PubMed]
==[https://www.nccn.org/ NCCN]==
*[https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf NCCN Guidelines - Breast Cancer]

=Neoadjuvant chemotherapy=
==ECH {{#subobject:6828f5|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ECH: '''<u>E</u>'''pirubicin, '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''erceptin (Trastuzumab)
===Regimen {{#subobject:436755|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.sciencedirect.com/science/article/pii/S1470204511703977 Untch et al. 2012 (GeparQuinto)]
|style="background-color:#1a9851"|Phase III (C)
|[[Complex_multipart_regimens#GeparQuinto|See link]]
| style="background-color:#91cf60" |[[Complex_multipart_regimens#GeparQuinto|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Chemotherapy====
*[[Epirubicin (Ellence)]] 90 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 8 mg/kg IV once on day 1
**Cycles 2 to 4: 6 mg/kg IV once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[#TH_.28Taxotere.29|TH (Taxotere)]] x 4, then [[Surgery#Breast_cancer_surgery|surgery]]
===References===
# '''GeparQuinto:''' Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer JU, Hilfrich J, Strumberg D, Fasching PA, Kreienberg R, Tesch H, Hanusch C, Gerber B, Rezai M, Jackisch C, Huober J, Kühn T, Nekljudova V, von Minckwitz G; German Breast Group (GBG); Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol. 2012 Feb;13(2):135-44. Epub 2012 Jan 17. [https://www.sciencedirect.com/science/article/pii/S1470204511703977 link to SD article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22257523 PubMed]

==FEC & H {{#subobject:d2476f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
FEC & H: '''<u>F</u>'''luorouracil, '''<u>E</u>'''pirubicin, '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''erceptin (Trastuzumab)
===Variant #1, IV trastuzumab {{#subobject:b4f490|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70329-7/fulltext Ismael et al. 2012 (HannaH)]
|style="background-color:#1a9851"|Randomized (C)
|[[Complex_multipart_regimens#HannaH|See link]]
|style="background-color:#eeee01"|[[Complex_multipart_regimens#HannaH|See link]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2017.74.0126 Pivot et al. 2018 (SB3-G31-BC)]
|style="background-color:#1a9851"|Phase III (C)
|[[Complex_multipart_regimens#SB3-G31-BC|See link]]
|style="background-color:#eeee01"|[[Complex_multipart_regimens#SB3-G31-BC|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[#TH_.28Taxotere.29|TH (IV)]] x 4
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once on day 1
*[[Epirubicin (Ellence)]] 75 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once on day 1
*[[Trastuzumab (Herceptin)]] 6 mg/kg IV once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*HannaH: [[Surgery#Breast_cancer_surgery|Surgery]]
*SB3-G31-BC: [[Surgery#Breast_cancer_surgery|Surgery]], then [[#Trastuzumab_monotherapy_2|adjuvant trastuzumab]] x 30 wk

===Variant #2, SC trastuzumab {{#subobject:febd45|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70329-7/fulltext Ismael et al. 2012 (HannaH)]
|style="background-color:#1a9851"|Randomized (E)
|[[Complex_multipart_regimens#HannaH|See link]]
|style="background-color:#eeee01"|[[Complex_multipart_regimens#HannaH|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[#TH_.28Taxotere.29|TH (SC)]] x 4
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once on day 1
*[[Epirubicin (Ellence)]] 75 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once on day 1
*[[Trastuzumab (Herceptin)]] 600 mg SC once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]

===Variant #3 {{#subobject:8e388e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/23/16/3676.long Buzdar et al. 2005]
|style="background-color:#1a9851"|Randomized (E)
|[[Complex_multipart_regimens#Buzdar_et_al._2005|See link]]
| style="background-color:#91cf60" |[[Complex_multipart_regimens#Buzdar_et_al._2005|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[#TH_.28Taxol.29|TH]] x 4
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once per day on days 1 & 4
*[[Epirubicin (Ellence)]] 75 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once on day 1
*[[Trastuzumab (Herceptin)]] 2 mg/kg IV once per day on days 1, 8, 15

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]

===References===
# Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005 Jun 1;23(16):3676-85. Epub 2005 Feb 28. [http://jco.ascopubs.org/content/23/16/3676.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15738535 PubMed]
## '''Update:''' Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS, Buchholz TA, Hortobagyi GN. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res. 2007 Jan 1;13(1):228-33. [http://clincancerres.aacrjournals.org/content/13/1/228.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17200359 PubMed]
# '''HannaH:''' Ismael G, Hegg R, Muehlbauer S, Heinzmann D, Lum B, Kim SB, Pienkowski T, Lichinitser M, Semiglazov V, Melichar B, Jackisch C. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol. 2012 Sep;13(9):869-78. Epub 2012 Aug 9. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70329-7/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22884505 PubMed]
# '''SB3-G31-BC:''' Pivot X, Bondarenko I, Nowecki Z, Dvorkin M, Trishkina E, Ahn JH, Vinnyk Y, Im SA, Sarosiek T, Chatterjee S, Wojtukiewicz MZ, Moiseyenko V, Shparyk Y, Bello M 3rd, Semiglazov V, Song S, Lim J. Phase III, randomized, double-blind study comparing the efficacy, safety, and immunogenicity of SB3 (trastuzumab biosimilar) and reference trastuzumab in patients treated with neoadjuvant therapy for human epidermal growth factor receptor 2-positive early breast cancer. J Clin Oncol. 2018 Apr 1;36(10):968-974. Epub 2018 Jan 26. [http://ascopubs.org/doi/full/10.1200/JCO.2017.74.0126 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29373094 PubMed]

==Lapatinib & Trastuzumab {{#subobject:9cbcb2|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:9ac66b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61847-3/fulltext Baselga et al. 2012 (NeoALTTO)]
|style="background-color:#1a9851"|Phase III (E)
|[[Complex_multipart_regimens#NeoALTTO|See link]]
|[[Complex_multipart_regimens#NeoALTTO|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Chemotherapy====
*[[Lapatinib (Tykerb)]] 1000 mg PO once per day
*[[Trastuzumab (Herceptin)]] 4 mg/kg IV once on day 1, then 2 mg/kg IV once per week

'''6-week course'''
====Subsequent treatment====
*[[#THL_.28Taxol.29|THL (Taxol)]] x 12 wk, then [[Surgery#Breast_cancer_surgery|surgery]]

===References===
# '''NeoALTTO:''' Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horváth Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M; NeoALTTO Study Team. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012 Feb 18;379(9816):633-40. Epub 2012 Jan 17. Erratum in: Lancet. 2012 Feb 18;379(9816):616. Dosage error in published abstract; MEDLINE/PubMed abstract corrected. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61847-3/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705192/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22257673 PubMed]
## '''Update:''' de Azambuja E, Holmes AP, Piccart-Gebhart M, Holmes E, Di Cosimo S, Swaby RF, Untch M, Jackisch C, Lang I, Smith I, Boyle F, Xu B, Barrios CH, Perez EA, Azim HA Jr, Kim SB, Kuemmel S, Huang CS, Vuylsteke P, Hsieh RK, Gorbunova V, Eniu A, Dreosti L, Tavartkiladze N, Gelber RD, Eidtmann H, Baselga J. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol. 2014 Sep;15(10):1137-46. Epub 2014 Aug 14. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70320-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25130998 PubMed]

==Neratinib & Paclitaxel {{#subobject:bd4482|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:3751fa|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5259558/ Park et al. 2016 (I-SPY 2)]
|style="background-color:#1a9851"|Adaptively Randomized Phase II (E)
|[[#TH_.28Taxol.29|TH]]
|style="background-color:#91cf60"|Seems to have superior pCR rate
|-
|}
====Chemotherapy====
*[[Neratinib (Nerlynx)]] 240 mg PO once per day
*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV once per week

====Supportive medications====
*[[Loperamide (Imodium)]] 4 mg PO on day 1 of [[Neratinib (Nerlynx)]], 2 mg PO 8 hours later, and then 2 mg PO twice per day for two weeks, then decreased per patient choice

'''12-week course'''
====Subsequent treatment====
*[[Breast_cancer#AC|AC]] or [[Breast_cancer#ddAC|ddAC]], then [[Surgery#Breast_cancer_surgery|surgery]]

===References===
<!-- Presented in part by Dr. Park at the 104th annual meeting of the American Association for Cancer Research, Washington, DC, April 6–10, 2013. -->
# '''I-SPY 2:''' Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA; I-SPY 2 Investigators. Adaptive randomization of neratinib in early breast cancer. N Engl J Med. 2016 Jul 7;375(1):11-22. [https://www.nejm.org/doi/full/10.1056/NEJMoa1513750 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5259558/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27406346 PubMed]

==TCHP (Taxotere) {{#subobject:CMR1|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
TCHP: '''<u>T</u>'''axotere (Docetaxel), '''<u>C</u>'''arboplatin, '''<u>H</u>'''erceptin (Trastuzumab), '''<u>P</u>'''ertuzumab<br>
===Regimen {{#subobject:CMV1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://annonc.oxfordjournals.org/content/24/9/2278.long Schneeweiss et al. 2013 (TRYPHAENA)]
|style="background-color:#1a9851"|Randomized Phase II (E)
|[[Complex_multipart_regimens#TRYPHAENA|See link]]
|style="background-color:#d3d3d3"|Not reported
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30716-7/fulltext Hurvitz et al. 2017 (KRISTINE)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Pertuzumab_.26_T-DM1|Pertuzumab & T-DM1]]
|style="background-color:#91cf60"|Seems to have superior pCR rate
|-
|}
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 8 mg/kg IV once on day 1
**Cycles 2 to 6: 6 mg/kg IV once on day 1
*[[Pertuzumab (Perjeta)]] as follows:
**Cycle 1: 840 mg IV once on day 1
**Cycles 2 to 6: 420 mg IV once on day 1

'''21-day cycle for 6 cycles'''

====Subsequent treatment====
*TRYPHAENA: [[Surgery#Breast_cancer_surgery|Surgery]], then further adjuvant treatment (radiotherapy, chemotherapy, hormonal treatment) according to local guidelines (a total of 1 year of trastuzumab was given)
*KRISTINE: [[Surgery#Breast_cancer_surgery|Surgery]]
===References===
# '''TRYPHAENA:''' Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai YF, Ratnayake J, McNally V, Ross G, Cortés J. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013 Sep;24(9):2278-84. Epub 2013 May 22. [http://annonc.oxfordjournals.org/content/24/9/2278.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23704196 PubMed]
# '''KRISTINE:''' Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang CS, Thompson AM, Harbeck N, Valero V, Stroyakovskiy D, Wildiers H, Campone M, Boileau JF, Beckmann MW, Afenjar K, Fresco R, Helms HJ, Xu J, Lin YG, Sparano J, Slamon D. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2018 Jan;19(1):115-126. Epub 2017 Nov 23. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30716-7/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29175149 PubMed]

==TH (Taxol) {{#subobject:647f67|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
TH: '''<u>T</u>'''axol (Paclitaxel) & '''<u>H</u>'''erceptin (Trastuzumab)
<br>T-T: '''<u>T</u>'''axol (Paclitaxel) & '''<u>T</u>'''rastuzumab
===Variant #1, weekly paclitaxel x 12, weekly trastuzumab {{#subobject:39d2af|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61847-3/fulltext Baselga et al. 2012 (NeoALTTO)]
|style="background-color:#1a9851"|Phase III (C)
|[[Complex_multipart_regimens#NeoALTTO|See link]]
|[[Complex_multipart_regimens#NeoALTTO|See link]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4176878/ Buzdar et al. 2013 (ACOSOG Z1041)]
|style="background-color:#1a9851"|Phase III (*)
|[[Complex_multipart_regimens#ACOSOG_Z1041|See link]]
|style="background-color:#ffffbf"|[[Complex_multipart_regimens#ACOSOG_Z1041|See link]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5259558/ Park et al. 2016 (I-SPY 2)]
|style="background-color:#1a9851"|Adaptively Randomized Phase II (C)
|[[#Neratinib_.26_Paclitaxel|Neratinib & Paclitaxel]]
|style="background-color:#fc8d59"|Seems to have inferior pCR rate
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment. Patients in NeoALTTO had already undergone trastuzumab loading so would continue at the 2 mg/kg weekly dose. In ACOSOG Z1041, this portion of the regimen was used in both the control and experimental arms.''
====Preceding treatment====
*NeoALTTO: [[#Trastuzumab_monotherapy|Trastuzumab]] x 6 wk
*ACOSOG Z1041: [[Breast_cancer#FEC|FEC]] x 4
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV once per week
*[[Trastuzumab (Herceptin)]] as follows:
**Week 1: 4 mg/kg IV once
**Weeks 2 to 12: 2 mg/kg IV once per week

'''12-week course'''
====Subsequent treatment====
*NeoALTTO: [[Surgery#Breast_cancer_surgery|Surgery]], then [[Breast_cancer#FEC_2|adjuvant FEC]] x 3
*ACOSOG Z1041: [[Surgery#Breast_cancer_surgery|Surgery]]
*I-SPY 2: [[Breast_cancer#AC|AC]] or [[Breast_cancer#ddAC|ddAC]], then [[Surgery#Breast_cancer_surgery|surgery]]

===Variant #2, weekly paclitaxel x 12, q3wk trastuzumab {{#subobject:b061d7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30241-9/fulltext von Minckwitz et al. 2018 (LILAC)]
|style="background-color:#1a9851"|Phase III (C)
|Paclitaxel & ABP 980
|style="background-color:#ffffbf"|Inconclusive whether equivalent
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*Anthracycline-containing chemotherapy x 4
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV once per week
*[[Trastuzumab (Herceptin)]] as follows:
**Week 1: 8 mg/kg IV once
**Weeks 4 to 12: 6 mg/kg IV once every 3 weeks

'''12-week course'''
====Subsequent treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]

===Variant #3, weekly paclitaxel x 16 {{#subobject:068233|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980567/ Carey et al. 2015 (CALGB 40601)]
|rowspan=2 style="background-color:#1a9851"|Phase III (C)
|1. [[#THL_.28Taxol.29|THL]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#TL_.28Taxol.29|TL]]
| style="background-color:#d3d3d3" |Not reported
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV once per week
*[[Trastuzumab (Herceptin)]] as follows:
**Week 1: 4 mg/kg IV once
**Weeks 2 to 16: 2 mg/kg IV once per week

'''16-week course'''
====Subsequent treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]], then adjuvant [[Breast_cancer#AC_2|AC]] x 4 or [[Breast_cancer#ddAC_2|ddAC]] x 4, then [[#Trastuzumab_monotherapy_2|trastuzumab]] for 36 weeks was recommended but not mandated

===Variant #4, paclitaxel 3 out of 4 weeks {{#subobject:b18877|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70411-X/fulltext Robidoux et al. 2013 (NSABP B-41)]
|rowspan=2 style="background-color:#1a9851"|Phase III (C)
|1. [[#THL_.28Taxol.29|THL]]
|style="background-color:#fee08b"|Might have inferior pCR rate
|-
|2. [[#TL_.28Taxol.29|TL]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[Breast_cancer#AC|AC]] x 4 
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV once per day on days 1, 8, 15
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 4 mg/kg IV once on day 1, then 2 mg/kg IV once per day on days 8, 15, 22
**Cycles 2 to 4: 2 mg/kg IV once per day on days 1, 8, 15, 22

'''28-day cycle for 4 cycles'''

====Subsequent treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]], then [[#Trastuzumab_monotherapy_2|adjuvant trastuzumab]] for a total of 52 weeks of therapy.''

===Variant #5, q3wk, paclitaxel 175 mg/m<sup>2</sup> {{#subobject:7573a9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30241-9/fulltext von Minckwitz et al. 2018 (LILAC)]
|style="background-color:#1a9851"|Phase III (C)
|Paclitaxel & ABP 980
|style="background-color:#ffffbf"|Inconclusive whether equivalent
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*Anthracycline-containing chemotherapy x 4
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV once on day 1
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 8 mg/kg IV once
**Cycles 2 to 4: 6 mg/kg IV once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]

===Variant #6, q3wk, paclitaxel 225 mg/m<sup>2</sup> {{#subobject:8e388e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/23/16/3676.long Buzdar et al. 2005]
|style="background-color:#1a9851"|Randomized (E)
|[[Complex_multipart_regimens#Buzdar_et_al._2005|See link]]
| style="background-color:#91cf60" |[[Complex_multipart_regimens#Buzdar_et_al._2005|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 225 mg/m<sup>2</sup> IV continuous infusion over 24 hours on day 1
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 4 mg/kg IV once on day 1 prior to first dose of paclitaxel, then 2 mg/kg IV once per day on days 8 & 15
**Cycles 2 to 4: 2 mg/kg IV once per day on days 1, 8, 15

'''21-day cycle for 4 cycles'''

====Subsequent treatment====
*[[#FEC_.26_H|FEC & H]]

===References===
# Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005 Jun 1;23(16):3676-85. Epub 2005 Feb 28. [http://jco.ascopubs.org/content/23/16/3676.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15738535 PubMed]
## '''Update:''' Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS, Buchholz TA, Hortobagyi GN. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res. 2007 Jan 1;13(1):228-33. [http://clincancerres.aacrjournals.org/content/13/1/228.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17200359 PubMed]
# '''NeoALTTO:''' Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horváth Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M; NeoALTTO Study Team. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012 Feb 18;379(9816):633-40. Epub 2012 Jan 17. Erratum in: Lancet. 2012 Feb 18;379(9816):616. Dosage error in published abstract; MEDLINE/PubMed abstract corrected. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61847-3/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705192/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22257673 PubMed]
## '''Update:''' de Azambuja E, Holmes AP, Piccart-Gebhart M, Holmes E, Di Cosimo S, Swaby RF, Untch M, Jackisch C, Lang I, Smith I, Boyle F, Xu B, Barrios CH, Perez EA, Azim HA Jr, Kim SB, Kuemmel S, Huang CS, Vuylsteke P, Hsieh RK, Gorbunova V, Eniu A, Dreosti L, Tavartkiladze N, Gelber RD, Eidtmann H, Baselga J. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol. 2014 Sep;15(10):1137-46. Epub 2014 Aug 14. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70320-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25130998 PubMed]
# '''NSABP B-41:''' Robidoux A, Tang G, Rastogi P, Geyer CE Jr, Azar CA, Atkins JN, Fehrenbacher L, Bear HD, Baez-Diaz L, Sarwar S, Margolese RG, Farrar WB, Brufsky AM, Shibata HR, Bandos H, Paik S, Costantino JP, Swain SM, Mamounas EP, Wolmark N. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol. 2013 Nov;14(12):1183-92. Epub 2013 Oct 4. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70411-X/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24095300 PubMed]
# '''ACOSOG Z1041:''' Buzdar AU, Suman VJ, Meric-Bernstam F, Leitch AM, Ellis MJ, Boughey JC, Unzeitig G, Royce M, McCall LM, Ewer MS, Hunt KK; American College of Surgeons Oncology Group investigators. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial. Lancet Oncol. 2013 Dec;14(13):1317-25. Epub 2013 Nov 13. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70502-3/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4176878/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24239210 PubMed]
# '''CALGB 40601:''' Carey LA, Berry DA, Cirrincione CT, Barry WT, Pitcher BN, Harris LN, Ollila DW, Krop IE, Henry NL, Weckstein DJ, Anders CK, Singh B, Hoadley KA, Iglesia M, Cheang MC, Perou CM, Winer EP, Hudis CA. Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus trastuzumab with or without lapatinib. J Clin Oncol. 2016 Feb 20;34(6):542-9. Epub 2015 Nov 2. [http://ascopubs.org/doi/full/10.1200/JCO.2015.62.1268 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980567/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26527775 PubMed]
<!-- Presented in part by Dr. Park at the 104th annual meeting of the American Association for Cancer Research, Washington, DC, April 6–10, 2013. -->
# '''I-SPY 2:''' Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA; I-SPY 2 Investigators. Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med. 2016 Jul 7;375(1):11-22. [https://www.nejm.org/doi/full/10.1056/NEJMoa1513750 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5259558/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27406346 PubMed]
# '''LILAC:''' von Minckwitz G, Colleoni M, Kolberg HC, Morales S, Santi P, Tomasevic Z, Zhang N, Hanes V. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2018 Jul;19(7):987-998.Epub 2018 Jun 4. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30241-9/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29880292 PubMed]

==TH (Taxotere) {{#subobject:ffc0e4|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
TH: '''<u>T</u>'''axotere (Docetaxel) & '''<u>H</u>'''erceptin (Trastuzumab)
<br>DH: '''<u>D</u>'''ocetaxel & '''<u>H</u>'''erceptin (Trastuzumab)
===Variant #1, 75 mg/m<sup>2</sup> q3wk docetaxel, q3wk trastuzumab (IV) {{#subobject:7391c0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70329-7/fulltext Ismael et al. 2012 (HannaH)]
|style="background-color:#1a9851"|Randomized (C)
|[[Complex_multipart_regimens#HannaH|See link]]
|style="background-color:#eeee01"|[[Complex_multipart_regimens#HannaH|See link]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2017.74.0126 Pivot et al. 2018 (SB3-G31-BC)]
|style="background-color:#1a9851"|Randomized (C)
|[[Complex_multipart_regimens#SB3-G31-BC|See link]]
|style="background-color:#eeee01"|[[Complex_multipart_regimens#SB3-G31-BC|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 8 mg/kg IV once on day 1
**Cycles 2 to 4: 6 mg/kg IV once on day 1

'''21-day cycle for 4 cycles'''

====Subsequent treatment====
*[[#FEC_.26_H|FEC & H (IV)]]

===Variant #2, 75 mg/m<sup>2</sup> q3wk docetaxel, q3wk trastuzumab (SC) {{#subobject:d87acc|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70329-7/fulltext Ismael et al. 2012 (HannaH)]
|style="background-color:#1a9851"|Randomized (E)
|[[Complex_multipart_regimens#HannaH|See link]]
|style="background-color:#eeee01"|[[Complex_multipart_regimens#HannaH|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Trastuzumab (Herceptin)]] 600 mg SC once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[#FEC_.26_H|FEC & H (SC)]]

===Variant #3, 100 mg/m<sup>2</sup> q3wk docetaxel, weekly trastuzumab {{#subobject:361b97|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pubmed/14715110 Van Pelt et al. 2003]
|style="background-color:#91cf61"|Phase II
|OCR: 77%
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Chemotherapy====
*[[Docetaxel (Taxotere)]] as follows:
**Cycle 0: no treatment
**Cycles 1 to 4: 100 mg/m<sup>2</sup> IV once on day 1
*[[Trastuzumab (Herceptin)]] 4 mg/kg IV once on day 1, then 2 mg/kg IV once per week

'''21-day cycle for 5 cycles'''

====Subsequent treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]], then [[Breast_cancer#AC_2|AC]] x 4, then [[#Trastuzumab_monotherapy_2|H]] x 52 wk

===Variant #1, 100 mg/m<sup>2</sup> q3wk docetaxel, q3wk trastuzumab {{#subobject:a889a0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.sciencedirect.com/science/article/pii/S1470204511703977 Untch et al. 2012 (GeparQuinto)]
|style="background-color:#1a9851"|Phase III (C)
|[[Complex_multipart_regimens#GeparQuinto|See link]]
| style="background-color:#91cf60" |[[Complex_multipart_regimens#GeparQuinto|See link]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3950860/ Alba et al. 2014 (GEICAM 2006-14)]
|style="background-color:#1a9851"|Phase III (C)
|TL (Taxotere)
| style="background-color:#1a9850" |Superior pCR rate
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment. No loading dose was used for trastuzumab in GeparQuinto because the load occurred during the ECH part of the regimen.''
====Preceding treatment====
*GeparQuinto: [[#ECH|ECH]] x 4
*GEICAM 2006-14: [[Breast_cancer#EC|EC]] x 4
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 100 mg/m<sup>2</sup> IV once on day 1
*[[Trastuzumab (Herceptin)]] 6 mg/kg IV once on day 1
**GEICAM 2006-14 used a loading dose of 8 mg/kg in cycle 1

'''21-day cycle for 4 cycles'''

====Subsequent treatment====
*GeparQuinto: [[Surgery#Breast_cancer_surgery|Surgery]], then [[#Trastuzumab_monotherapy_2|adjuvant trastuzumab]] for 1 year total
*GEICAM 2006-14: [[Surgery#Breast_cancer_surgery|Surgery]]
===References===
# Van Pelt AE, Mohsin S, Elledge RM, Hilsenbeck SG, Gutierrez MC, Lucci A Jr, Kalidas M, Granchi T, Scott BG, Allred DC, Chang JC. Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin Breast Cancer. 2003 Dec;4(5):348-53. '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/14715110 PubMed]
# '''GeparQuinto:''' Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer JU, Hilfrich J, Strumberg D, Fasching PA, Kreienberg R, Tesch H, Hanusch C, Gerber B, Rezai M, Jackisch C, Huober J, Kühn T, Nekljudova V, von Minckwitz G; German Breast Group (GBG); Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol. 2012 Feb;13(2):135-44. Epub 2012 Jan 17. [https://www.sciencedirect.com/science/article/pii/S1470204511703977 link to SD article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22257523 PubMed]
# '''HannaH:''' Ismael G, Hegg R, Muehlbauer S, Heinzmann D, Lum B, Kim SB, Pienkowski T, Lichinitser M, Semiglazov V, Melichar B, Jackisch C. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol. 2012 Sep;13(9):869-78. Epub 2012 Aug 9. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70329-7/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22884505 PubMed]
# '''GEICAM 2006-14:''' Alba E, Albanell J, de la Haba J, Barnadas A, Calvo L, Sánchez-Rovira P, Ramos M, Rojo F, Burgués O, Carrasco E, Caballero R, Porras I, Tibau A, Cámara MC, Lluch A. Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial. Br J Cancer. 2014 Mar 4;110(5):1139-47. Epub 2014 Jan 23. [https://www.nature.com/articles/bjc2013831 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3950860/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24457911 PubMed]
# '''SB3-G31-BC:''' Pivot X, Bondarenko I, Nowecki Z, Dvorkin M, Trishkina E, Ahn JH, Vinnyk Y, Im SA, Sarosiek T, Chatterjee S, Wojtukiewicz MZ, Moiseyenko V, Shparyk Y, Bello M 3rd, Semiglazov V, Song S, Lim J. Phase III, randomized, double-blind study comparing the efficacy, safety, and immunogenicity of SB3 (trastuzumab biosimilar) and reference trastuzumab in patients treated with neoadjuvant therapy for human epidermal growth factor receptor 2-positive early breast cancer. J Clin Oncol. 2018 Apr 1;36(10):968-974. Epub 2018 Jan 26. [http://ascopubs.org/doi/full/10.1200/JCO.2017.74.0126 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29373094 PubMed]

==THL (Taxol) {{#subobject:6992f4|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
THL: '''<u>T</u>'''axol (Paclitaxel), '''<u>H</u>'''erceptin (Trastuzumab), '''<u>L</u>'''apatinib
===Variant #1, weekly paclitaxel x 12 {{#subobject:459c75|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61847-3/fulltext Baselga et al. 2012 (NeoALTTO)]
|style="background-color:#1a9851"|Phase III (E)
|[[Complex_multipart_regimens#NeoALTTO|See link]]
|[[Complex_multipart_regimens#NeoALTTO|See link]]
|-
|}
====Preceding treatment====
*[[#Lapatinib_.26_Trastuzumab|Lapatinib & Trastuzumab]] x 6 wk
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV once per week
*[[Trastuzumab (Herceptin)]] 2 mg/kg IV once per week
*[[Lapatinib (Tykerb)]] 1000 mg PO once per day

'''12-week course'''
====Subsequent treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]], then [[Breast_cancer#FEC_2|adjuvant FEC]] x 3

===Variant #2, weekly paclitaxel x 16 {{#subobject:1b4c0a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980567/ Carey et al. 2015 (CALGB 40601)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#TH_.28Taxol.29|TH]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#TL_.28Taxol.29|TL]]
| style="background-color:#d3d3d3" |Not reported
|-
|}
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV once per week
*[[Trastuzumab (Herceptin)]] as follows:
**Week 1: 4 mg/kg IV once
**Weeks 2 to 16: 2 mg/kg IV once per week
*[[Lapatinib (Tykerb)]] 750 mg PO once per day

'''16-week course'''
====Subsequent treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]; adjuvant [[Breast_cancer#AC_2|AC]] x 4 or [[Breast_cancer#ddAC_2|ddAC]] x 4, then [[#Trastuzumab_monotherapy_2|trastuzumab]] for 36 weeks was recommended but not mandated

===Variant #3, paclitaxel 3 out of 4 weeks {{#subobject:ca2389|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70411-X/fulltext Robidoux et al. 2013 (NSABP B-41)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#TH_.28Taxol.29|TH]]
|style="background-color:#d9ef8b"|Might have superior pCR rate
|-
|2. [[#TL_.28Taxol.29|TL]]
|style="background-color:#d9ef8b"|Might have superior pCR rate
|-
|}
====Preceding treatment====
*[[Breast_cancer#AC|AC]] x 4 
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV once per day on days 1, 8, 15
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 4 mg/kg IV once on day 1, then 2 mg/kg IV once per day on days 8, 15, 22
**Cycles 2 to 4: 2 mg/kg IV once per day on days 1, 8, 15, 22
*[[Lapatinib (Tykerb)]] 750 mg PO once per day

'''28-day cycle for 4 cycles'''
====Subsequent treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]], then [[#Trastuzumab_monotherapy_2|adjuvant trastuzumab]] for a total of 52 weeks of therapy

===References===
# '''NeoALTTO:''' Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horváth Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M; NeoALTTO Study Team. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012 Feb 18;379(9816):633-40. Epub 2012 Jan 17. Erratum in: Lancet. 2012 Feb 18;379(9816):616. Dosage error in published abstract; MEDLINE/PubMed abstract corrected. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61847-3/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705192/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22257673 PubMed]
## '''Update:''' de Azambuja E, Holmes AP, Piccart-Gebhart M, Holmes E, Di Cosimo S, Swaby RF, Untch M, Jackisch C, Lang I, Smith I, Boyle F, Xu B, Barrios CH, Perez EA, Azim HA Jr, Kim SB, Kuemmel S, Huang CS, Vuylsteke P, Hsieh RK, Gorbunova V, Eniu A, Dreosti L, Tavartkiladze N, Gelber RD, Eidtmann H, Baselga J. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol. 2014 Sep;15(10):1137-46. Epub 2014 Aug 14. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70320-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25130998 PubMed]
# '''NSABP B-41:''' Robidoux A, Tang G, Rastogi P, Geyer CE Jr, Azar CA, Atkins JN, Fehrenbacher L, Bear HD, Baez-Diaz L, Sarwar S, Margolese RG, Farrar WB, Brufsky AM, Shibata HR, Bandos H, Paik S, Costantino JP, Swain SM, Mamounas EP, Wolmark N. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol. 2013 Nov;14(12):1183-92. Epub 2013 Oct 4. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70411-X/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24095300 PubMed]
# '''CALGB 40601:''' Carey LA, Berry DA, Cirrincione CT, Barry WT, Pitcher BN, Harris LN, Ollila DW, Krop IE, Henry NL, Weckstein DJ, Anders CK, Singh B, Hoadley KA, Iglesia M, Cheang MC, Perou CM, Winer EP, Hudis CA. Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus trastuzumab with or without lapatinib. J Clin Oncol. 2016 Feb 20;34(6):542-9. Epub 2015 Nov 2. [http://ascopubs.org/doi/full/10.1200/JCO.2015.62.1268 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980567/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26527775 PubMed]

==THP (Taxotere) {{#subobject:24b376|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
THP: '''<u>T</u>'''axotere (Docetaxel), '''<u>H</u>'''erceptin (Trastuzumab), '''<u>P</u>'''ertuzumab
===Variant #1, 3 cycles with loading doses {{#subobject:fb33dc|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://annonc.oxfordjournals.org/content/24/9/2278.long Schneeweiss et al. 2013 (TRYPHAENA)]
|style="background-color:#1a9851"|Randomized Phase II (E)
|[[Complex_multipart_regimens#TRYPHAENA|See link]]
|style="background-color:#d3d3d3"|Not reported
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[Breast_cancer#FEC|FEC]] x 3
====Chemotherapy====
*[[Docetaxel (Taxotere)]] as follows:
**Cycle 1 (4, overall): 75 mg/m<sup>2</sup> IV once on day 1
**Cycles 2 & 3 (5 & 6, overall), if no toxic effects occurred: 100 mg/m<sup>2</sup> IV once on day 1
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 8 mg/kg IV once on day 1
**Cycles 2 to 4: 6 mg/kg IV once on day 1
*[[Pertuzumab (Perjeta)]] as follows:
**Cycle 1: 840 mg IV once on day 1
**Cycles 2 to 4: 420 mg IV once on day 1

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]], then further adjuvant treatment (radiotherapy, chemotherapy, hormonal treatment) according to local guidelines (a total of 1 year of trastuzumab was given)

===Variant #2, 3 cycles without loading doses {{#subobject:52f6c6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://annonc.oxfordjournals.org/content/24/9/2278.long Schneeweiss et al. 2013 (TRYPHAENA)]
|style="background-color:#1a9851"|Randomized Phase II (E)
|[[Complex_multipart_regimens#TRYPHAENA|See link]]
|style="background-color:#d3d3d3"|Not reported
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*FEC & HP x 3
====Chemotherapy====
*[[Docetaxel (Taxotere)]] as follows:
**Cycle 1 (4, overall): 75 mg/m<sup>2</sup> IV once on day 1
**Cycles 2 & 3 (5 & 6, overall), if no toxic effects occurred: 100 mg/m<sup>2</sup> IV once on day 1
*[[Trastuzumab (Herceptin)]] 6 mg/kg IV once on day 1
*[[Pertuzumab (Perjeta)]] 420 mg IV once on day 1

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]], then further adjuvant treatment (radiotherapy, chemotherapy, hormonal treatment) according to local guidelines (a total of 1 year of trastuzumab was given)

===Variant #3, 4 cycles with loading doses {{#subobject:3f1974|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=3|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70336-9/fulltext Gianni et al. 2011 (NeoSphere)]
|rowspan=3 style="background-color:#1a9851"|Randomized Phase II (E)
|1. Docetaxel & Pertuzumab
|style="background-color:#ffffbf"|Seems not superior
|-
|2. Pertuzumab & Trastuzumab
|style="background-color:#ffffbf"|Seems not superior
|-
|3. TH
|style="background-color:#91cf60"|Seems to have superior pCR rate
|-
|[http://annonc.oxfordjournals.org/content/24/9/2278.long Schneeweiss et al. 2013 (TRYPHAENA)]
|style="background-color:#1a9851"|Randomized Phase II (E)
|[[Complex_multipart_regimens#TRYPHAENA|See link]]
|style="background-color:#d3d3d3"|Not reported
|-
|}
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1
**Based on tolerability, investigators could increase dose to 100 mg/m<sup>2</sup> IV once on day 1
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 8 mg/kg IV once on day 1
**Cycles 2 to 4: 6 mg/kg IV once on day 1
*[[Pertuzumab (Perjeta)]] as follows:
**Cycle 1: 840 mg IV once on day 1
**Cycles 2 to 4: 420 mg IV once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]], then [[#FEC_.26_H_2|adjuvant FEC & H]]

===References===
# '''NeoSphere:''' Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012 Jan;13(1):25-32. Epub 2011 Dec 6. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70336-9/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22153890 PubMed]
## '''Update:''' Gianni L, Pienkowski T, Im YH, Tseng LM, Liu MC, Lluch A, Starosławska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi GV, Magazzù D, McNally V, Douthwaite H, Ross G, Valagussa P. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016 Jun;17(6):791-800. Epub 2016 May 11. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)00163-7/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27179402 PubMed]
# '''TRYPHAENA:''' Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai YF, Ratnayake J, McNally V, Ross G, Cortés J. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013 Sep;24(9):2278-84. Epub 2013 May 22. [http://annonc.oxfordjournals.org/content/24/9/2278.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23704196 PubMed]

==TL (Taxol) {{#subobject:af5af0|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
TL: '''<u>T</u>'''axol (Paclitaxel) & '''<u>L</u>'''apatinib
===Variant #1, weekly paclitaxel x 12 {{#subobject:bed34f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61847-3/fulltext Baselga et al. 2012 (NeoALTTO)]
|style="background-color:#1a9851"|Phase III (E)
|[[Complex_multipart_regimens#NeoALTTO|See link]]
|[[Complex_multipart_regimens#NeoALTTO|See link]]
|-
|}
====Preceding treatment====
*Lapatinib x 6 wk
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV once per week
*[[Lapatinib (Tykerb)]] 1500 mg PO once per day

'''12-week course'''
====Subsequent treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]], then [[Breast_cancer#FEC_2|adjuvant FEC]] x 3

===Variant #2, weekly paclitaxel x 16 {{#subobject:8aae8f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980567/ Carey et al. 2015 (CALGB 40601)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#TH_.28Taxol.29|TH]]
| style="background-color:#d3d3d3" |Not reported
|-
|2. [[#THL_.28Taxol.29|THL]]
| style="background-color:#d3d3d3" |Not reported
|-
|}
''Note: this arm was closed early.''
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV once per week
*[[Lapatinib (Tykerb)]] 1500 mg PO once per day

'''16-week course'''
====Subsequent treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]; adjuvant [[Breast_cancer#AC_2|AC]] x 4 or [[Breast_cancer#ddAC_2|ddAC]] x 4, then [[#Trastuzumab_monotherapy_2|trastuzumab]] for 36 weeks was recommended but not mandated

===Variant #3, paclitaxel 3 out of 4 weeks {{#subobject:6dda48|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70411-X/fulltext Robidoux et al. 2013 (NSABP B-41)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#TH_.28Taxol.29|TH]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#THL_.28Taxol.29|THL]]
|style="background-color:#fee08b"|Might have inferior pCR rate
|-
|}
====Preceding treatment====
*[[Breast_cancer#AC|AC]] x 4 
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV once per day on days 1, 8, 15
*[[Lapatinib (Tykerb)]] 1250 mg PO once per day

'''28-day cycle for 4 cycles'''
====Subsequent treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]], then [[#Trastuzumab_monotherapy_2|adjuvant trastuzumab]] for a total of 52 weeks of therapy
===References===
# '''NeoALTTO:''' Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horváth Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M; NeoALTTO Study Team. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012 Feb 18;379(9816):633-40. Epub 2012 Jan 17. Erratum in: Lancet. 2012 Feb 18;379(9816):616. Dosage error in published abstract; MEDLINE/PubMed abstract corrected. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61847-3/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705192/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22257673 PubMed]
## '''Update:''' de Azambuja E, Holmes AP, Piccart-Gebhart M, Holmes E, Di Cosimo S, Swaby RF, Untch M, Jackisch C, Lang I, Smith I, Boyle F, Xu B, Barrios CH, Perez EA, Azim HA Jr, Kim SB, Kuemmel S, Huang CS, Vuylsteke P, Hsieh RK, Gorbunova V, Eniu A, Dreosti L, Tavartkiladze N, Gelber RD, Eidtmann H, Baselga J. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol. 2014 Sep;15(10):1137-46. Epub 2014 Aug 14. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70320-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25130998 PubMed]
# '''NSABP B-41:''' Robidoux A, Tang G, Rastogi P, Geyer CE Jr, Azar CA, Atkins JN, Fehrenbacher L, Bear HD, Baez-Diaz L, Sarwar S, Margolese RG, Farrar WB, Brufsky AM, Shibata HR, Bandos H, Paik S, Costantino JP, Swain SM, Mamounas EP, Wolmark N. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol. 2013 Nov;14(12):1183-92. Epub 2013 Oct 4. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70411-X/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24095300 PubMed]
# '''CALGB 40601:''' Carey LA, Berry DA, Cirrincione CT, Barry WT, Pitcher BN, Harris LN, Ollila DW, Krop IE, Henry NL, Weckstein DJ, Anders CK, Singh B, Hoadley KA, Iglesia M, Cheang MC, Perou CM, Winer EP, Hudis CA. Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus trastuzumab with or without lapatinib. J Clin Oncol. 2016 Feb 20;34(6):542-9. Epub 2015 Nov 2. [http://ascopubs.org/doi/full/10.1200/JCO.2015.62.1268 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980567/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26527775 PubMed]

==T-DM1 monotherapy {{#subobject:ef98f0|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
T-DM1: '''<u>T</u>'''rastuzumab-'''<u>DM1</u>''' (ado-Trastuzumab emtansine)
===Regimen {{#subobject:91b517|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://ascopubs.org/doi/full/10.1200/JCO.2016.71.9815 Harbeck et al. 2017 (WGSG ADAPT)]
|rowspan=2 style="background-color:#1a9851"|Randomized Phase II (E)
|1. [[#T-DM1_.26_ET|T-DM1 & ET]]
|style="background-color:#d0d0d0"|Not reported
|-
|2. [[#Trastuzumab_.26_ET|Trastuzumab & ET]]
|style="background-color:#1a9850"|Superior pCR rate
|-
|}
====Chemotherapy====
*[[Ado-trastuzumab emtansine (Kadcyla)]] 3.6 mg/kg IV once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]] was performed within 3 weeks of the end of therapy. Adjuvant therapy consisted of [[Breast_cancer#EC_2|EC]], then [[#TH_.28Taxol.29_2|TH (Taxol)]], unless the patient had pCR in which case adjuvant therapy was optional

===References===
# Harbeck N, Gluz O, Christgen M, Kates RE, Braun M, Küemmel S, Schumacher C, Potenberg J, Kraemer S, Kleine-Tebbe A, Augustin D, Aktas B, Forstbauer H, Tio J, von Schumann R, Liedtke C, Grischke EM, Schumacher J, Wuerstlein R, Kreipe HH, Nitz UA. De-escalation strategies in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (BC): Final analysis of the West German Study Group Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early BC HER2- and hormone receptor-positive phase II randomized trial-efficacy, safety, and predictive markers for 12 weeks of neoadjuvant trastuzumab emtansine with or without endocrine therapy (ET) versus trastuzumab plus ET. J Clin Oncol. 2017 Sep 10;35(26):3046-3054. Epub 2017 Jul 6. [http://ascopubs.org/doi/full/10.1200/JCO.2016.71.9815 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28682681 PubMed]

==T-DM1 & ET {{#subobject:207386|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
T-DM1 & ET: '''<u>T</u>'''rastuzumab-DM1 (ado-Trastuzumab emtansine) & '''<u>E</u>'''ndocrine '''<u>T</u>'''herapy
===Regimen {{#subobject:b28ce1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://ascopubs.org/doi/full/10.1200/JCO.2016.71.9815 Harbeck et al. 2017 (WGSG ADAPT)]
|rowspan=2 style="background-color:#1a9851"|Randomized Phase II (E)
|1. [[#T-DM1_monotherapy|T-DM1]]
|style="background-color:#d0d0d0"|Not reported
|-
|2. [[#Trastuzumab_.26_ET|Trastuzumab & ET]]
|style="background-color:#1a9850"|Superior pCR rate
|-
|}
====Chemotherapy====
*[[Ado-trastuzumab emtansine (Kadcyla)]] 3.6 mg/kg IV once on day 1
*Endocrine therapy as follows:
**Premenopausal women: [[Tamoxifen (Nolvadex)]] recommended
**[[:Category:GnRH_agonists|GnRH analogs]] were also allowed
**Postmenopausal women: [[:Category:Aromatase inhibitors|Aromatase inhibitor]] recommended

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]] was performed within 3 weeks of the end of therapy. Adjuvant therapy consisted of [[Breast_cancer#EC_2|EC]], then [[#TH_.28Taxol.29_2|TH (Taxol)]], unless the patient had pCR in which case adjuvant therapy was optional

===References===
# Harbeck N, Gluz O, Christgen M, Kates RE, Braun M, Küemmel S, Schumacher C, Potenberg J, Kraemer S, Kleine-Tebbe A, Augustin D, Aktas B, Forstbauer H, Tio J, von Schumann R, Liedtke C, Grischke EM, Schumacher J, Wuerstlein R, Kreipe HH, Nitz UA. De-escalation strategies in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (BC): Final analysis of the West German Study Group Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early BC HER2- and hormone receptor-positive phase II randomized trial-efficacy, safety, and predictive markers for 12 weeks of neoadjuvant trastuzumab emtansine with or without endocrine therapy (ET) versus trastuzumab plus ET. J Clin Oncol. 2017 Sep 10;35(26):3046-3054. Epub 2017 Jul 6. [http://ascopubs.org/doi/full/10.1200/JCO.2016.71.9815 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28682681 PubMed]

==Trastuzumab monotherapy {{#subobject:9cbcb2|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:9ac66b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61847-3/fulltext Baselga et al. 2012 (NeoALTTO)]
|style="background-color:#1a9851"|Phase III (C)
|[[Complex_multipart_regimens#NeoALTTO|See link]]
|[[Complex_multipart_regimens#NeoALTTO|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Chemotherapy====
*[[Trastuzumab (Herceptin)]] 4 mg/kg IV once on day 1, then 2 mg/kg IV once per week

'''6-week course'''
====Subsequent treatment====
*[[#TH_.28Taxol.29|TH (Taxol)]] x 12 wk, then [[Surgery#Breast_cancer_surgery|surgery]]

===References===
# '''NeoALTTO:''' Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horváth Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M; NeoALTTO Study Team. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012 Feb 18;379(9816):633-40. Epub 2012 Jan 17. Erratum in: Lancet. 2012 Feb 18;379(9816):616. Dosage error in published abstract; MEDLINE/PubMed abstract corrected. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61847-3/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705192/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22257673 PubMed]
## '''Update:''' de Azambuja E, Holmes AP, Piccart-Gebhart M, Holmes E, Di Cosimo S, Swaby RF, Untch M, Jackisch C, Lang I, Smith I, Boyle F, Xu B, Barrios CH, Perez EA, Azim HA Jr, Kim SB, Kuemmel S, Huang CS, Vuylsteke P, Hsieh RK, Gorbunova V, Eniu A, Dreosti L, Tavartkiladze N, Gelber RD, Eidtmann H, Baselga J. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol. 2014 Sep;15(10):1137-46. Epub 2014 Aug 14. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70320-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25130998 PubMed]

==Trastuzumab & ET {{#subobject:b9d62c|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ET: '''<u>E</u>'''ndocrine '''<u>T</u>'''herapy
===Regimen {{#subobject:d0233|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2016.71.9815 Harbeck et al. 2017 (WGSG ADAPT)]
|style="background-color:#1a9851"|Randomized Phase II (C)
|[[#T-DM1_monotherapy|T-DM1]]<br> [[#T-DM1_.26_ET|T-DM1 & ET]]
|style="background-color:#d73027"|Inferior pCR rate
|-
|}
====Chemotherapy====
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 8 mg/kg IV once on day 1
**Cycles 2 to 4: 6 mg/kg IV once on day 1
*Endocrine therapy as follows:
**Premenopausal women: [[Tamoxifen (Nolvadex)]] recommended
**[[:Category:GnRH_agonists|GnRH analogs]] were also allowed
**Postmenopausal women: [[:Category:Aromatase inhibitors|Aromatase inhibitor]] recommended

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]] was performed within 3 weeks of the end of therapy. Adjuvant therapy consisted of [[Breast_cancer#EC_2|EC]], then [[#TH_.28Taxol.29_2|TH (Taxol)]], unless the patient had pCR in which case adjuvant therapy was optional

===References===
# Harbeck N, Gluz O, Christgen M, Kates RE, Braun M, Küemmel S, Schumacher C, Potenberg J, Kraemer S, Kleine-Tebbe A, Augustin D, Aktas B, Forstbauer H, Tio J, von Schumann R, Liedtke C, Grischke EM, Schumacher J, Wuerstlein R, Kreipe HH, Nitz UA. De-escalation strategies in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (BC): Final analysis of the West German Study Group Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early BC HER2- and hormone receptor-positive phase II randomized trial-efficacy, safety, and predictive markers for 12 weeks of neoadjuvant trastuzumab emtansine with or without endocrine therapy (ET) versus trastuzumab plus ET. J Clin Oncol. 2017 Sep 10;35(26):3046-3054. Epub 2017 Jul 6. [http://ascopubs.org/doi/full/10.1200/JCO.2016.71.9815 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28682681 PubMed]

=Neoadjuvant response criteria=

==Clinical response rate (cRR)==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
''Although fairly dated, some trials such as [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3107749/ ACOSOG Z1031] make use of the WHO criteria for response to neoadjuvant therapy. Included here primarily for historical purposes.''
===References===
# Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207-14. [https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19810101)47:1%3C207::AID-CNCR2820470134%3E3.0.CO;2-6/abstract link to original article]  [https://www.ncbi.nlm.nih.gov/pubmed/7459811 PubMed]

==Miller-Payne scoring system==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
*Grade 1: No change or some changes to individual malignant cells, but no reduction in overall cellularity
*Grade 2: Minor loss of tumor cells (up to 30%), but overall cellularity still high 
*Grade 3: An estimated 30 to 90% reduction in the number of tumor cells
*Grade 4: Marked disappearance of tumor cells such that only small clusters or widely dispersed individual cells remain (loss of greater than 90% of tumor cells) 
*Grade 5: No invasive cancer cells identifiable in sections from the site of the tumor (carcinoma ''in situ'' may be present) 
===References===
# Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I, Schofield A, Heys SD. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003 Oct;12(5):320-7. [http://www.thebreastonline.com/article/S0960-9776(03)00106-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/14659147 PubMed]

==Residual cancer burden (RCB)==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
*The RCB is calculated as follows: RCB = 1.4 (''f<sub>inv</sub>*d<sub>prim</sub>'')<sup>0.17</sup> + [4(1 - 0.75<sup>''LN''</sup>)''d<sub>met</sub>'']<sup>0.17</sup>
**where ''d<sub>prim</sub>'' is derived from the bidimensional diameters of the primary tumor bed in the resected specimen, ''f<sub>inv</sub>'' is the proportion of the primary tumor bed that contains invasive carcinoma, ''LN'' is the number of axillary lymph nodes containing metastatic carcinoma, and ''d<sub>met</sub>'' is the diameter of the largest metastasis in an axillary lymph node.
**The cut-off points are 1.36 and 3.28.
===References===
# Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007 Oct 1;25(28):4414-22. Epub 2007 Sep 4. [http://ascopubs.org/doi/full/10.1200/JCO.2007.10.6823 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17785706 PubMed]

==Residual disease in breast and nodes (RDBN)==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
*Level 1: pCR in breast and nodes with or without ''in situ'' carcinoma
*Levels 2 to 4: Residual disease, calculated as 0.2 (residual breast tumor size in cm) + index of involved nodes (0 for no positive nodes, 1 for 1 to 4 positive nodes, 2 for 5 to 7 positive nodes, and 3 for 8 positive nodes) + the Scarff–Bloom–Richardson grade (1, 2, or 3). The cut-off points are 3 and 4.3.
===References===
# Chollet P, Abrial C, Durando X, Thivat E, Tacca O, Mouret-Reynier MA, Leheurteur M, Kwiatkowski F, Dauplat J, Penault-Llorca F. A new prognostic classification after primary chemotherapy for breast cancer: residual disease in breast and nodes (RDBN). Cancer J. 2008 Mar-Apr;14(2):128-32. [https://insights.ovid.com/pubmed?pmid=18391619 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18391619 PubMed]

==Sataloff's classification==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
*Breast: 
**T-A: Total or nearly total therapeutic effect 
**T-B: Greater than 50% therapeutic effect
**T-C: Less than 50% therapeutic effect 
**T-D: No therapeutic effect
*Lymph node:
**N-A: Therapeutic effect but no metastasis
**N-B: No metastasis, no therapeutic effect
**N-C: Therapeutic effect but metastasis
**N-D: Metastasis, no therapeutic effect
===References===
# Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg. 1995 Mar;180(3):297-306. [https://www.ncbi.nlm.nih.gov/pubmed/7874340 PubMed]

==Tumor response ratio==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
Calculated as follows: Residual breast disease observed upon pathologic examination divided by the size of the tumor on the pre-neoadjuvant therapy image.
*TRR = 0: pathologic complete response (pCR)
*TRR greater than 0 up to 0.4: strong partial response
*TRR greater than 0.4 up to 1.0: weak partial response (WPR)
*TRR greater than 1.0: tumor growth
===References===
# Miller M, Ottesen RA, Niland JC, Kruper L, Chen SL, Vito C. Tumor response ratio predicts overall survival in breast cancer patients treated with neoadjuvant chemotherapy. Ann Surg Oncol. 2014 Oct;21(10):3317-23. Epub 2014 Jul 25. [https://link.springer.com/article/10.1245%2Fs10434-014-3922-0 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25059788 PubMed]

==ypTNM staging==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
This system is proprietary to the AJCC. Please [https://cancerstaging.org/Pages/default.aspx visit their site] or consult the AJCC Manual for further details.

=Adjuvant chemotherapy=
==ddTH (Taxol) {{#subobject:65c9a8|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ddTH: '''<u>d</u>'''ose-'''<u>d</u>'''ense '''<u>T</u>'''axol (Paclitaxel) & '''<u>H</u>'''erceptin (Trastuzumab)
===Regimen {{#subobject:4c0f4a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/26/8/1216.long Dang et al. 2008]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[Breast_cancer#ddAC_2|ddAC]] x 4
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1
*[[Trastuzumab (Herceptin)]] as follows:
**Week 1: 4 mg/kg IV once with first dose of paclitaxel
**Weeks 2 to 8: 2 mg/kg IV once per week

====Supportive medications====
*[[Pegfilgrastim (Neulasta)]] 6 mg SC once on day 2

'''14-day cycle for 4 cycles'''
====Subsequent treatment====
*[[#Trastuzumab_monotherapy_2|Trastuzumab for a total of 52 weeks]]

===References===
# Dang C, Fornier M, Sugarman S, Troso-Sandoval T, Lake D, D'Andrea G, Seidman A, Sklarin N, Dickler M, Currie V, Gilewski T, Moynahan ME, Drullinsky P, Robson M, Wasserheit-Leiblich C, Mills N, Steingart R, Panageas K, Norton L, Hudis C. The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. J Clin Oncol. 2008 Mar 10;26(8):1216-22. [http://jco.ascopubs.org/content/26/8/1216.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18323546 PubMed]

==ddTH (Taxotere) {{#subobject:61cda8|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ddTH: '''<u>d</u>'''ose-'''<u>d</u>'''ense '''<u>T</u>'''axotere (Docetaxel) & '''<u>H</u>'''erceptin (Trastuzumab)
===Regimen {{#subobject:1b2f4a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://academic.oup.com/annonc/article/26/7/1333/165655 Mavroudis et al. 2015 (HORG CT/04.23)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
====Preceding treatment====
*[[Breast_cancer#ddFEC|ddFEC]] x 4
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV over 60 minutes once on day 1
*[[Trastuzumab (Herceptin)]] as follows:
**Week 1: 6 mg/kg IV once with first dose of paclitaxel
**Weeks 2 to 8: 4 mg/kg IV once every 2 weeks
====Supportive medications====
*[[Filgrastim (Neupogen)]] 300 or 480 mcg SC once per day on days 3 to 10

'''14-day cycle for 4 cycles'''
====Subsequent treatment====
*[[#Trastuzumab_monotherapy_2|Trastuzumab for a total of 26 weeks]] versus [[#Trastuzumab_monotherapy_2|52 weeks]]

===References===
# '''HORG CT/04.23:''' Mavroudis D, Saloustros E, Malamos N, Kakolyris S, Boukovinas I, Papakotoulas P, Kentepozidis N, Ziras N, Georgoulias V; Breast Cancer Investigators of Hellenic Oncology Research Group (HORG). Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). Ann Oncol. 2015 Jul;26(7):1333-40. Epub 2015 May 1. [https://academic.oup.com/annonc/article/26/7/1333/165655 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25935793 PubMed]

==FEC & H {{#subobject:bdf58d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:0b4c6d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70336-9/fulltext Gianni et al. 2011 (NeoSphere)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*Neoadjuvant docetaxel & pertuzumab versus [[#THP_.28Taxotere.29|THP (Taxotere)]] versus pertuzumab & trastuzumab versus TH (Taxotere), then [[Surgery#Breast_cancer_surgery|surgery]]
====Chemotherapy====
*[[Fluorouracil (5-FU)]] as follows:
**Cycles 1 to 3: 600 mg/m<sup>2</sup> IV once on day 1
*[[Epirubicin (Ellence)]] as follows:
**Cycles 1 to 3: 90 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] as follows:
**Cycles 1 to 3: 600 mg/m<sup>2</sup> IV once on day 1
*[[Trastuzumab (Herceptin)]] 6 mg/kg IV once on day 1

'''21-day cycle for 18 cycles'''
====Subsequent treatment====
*Radiotherapy and/or hormone therapy for ER positive patients is given "per local guidelines"

===References===
# '''NeoSphere:''' Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012 Jan;13(1):25-32. Epub 2011 Dec 6. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70336-9/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22153890 PubMed]
## '''Update:''' Gianni L, Pienkowski T, Im YH, Tseng LM, Liu MC, Lluch A, Starosławska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi GV, Magazzù D, McNally V, Douthwaite H, Ross G, Valagussa P. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016 Jun;17(6):791-800. Epub 2016 May 11. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)00163-7/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27179402 PubMed]

==Lapatinib & Trastuzumab {{#subobject:da072f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:ec4131|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61847-3/fulltext Baselga et al. 2012 (NeoALTTO)]
|style="background-color:#1a9851"|Phase III (E)
|[[Complex_multipart_regimens#NeoALTTO|See link]]
|[[Complex_multipart_regimens#NeoALTTO|See link]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872016/ Piccart-Gebhart et al. 2015 (ALTTO)]
|style="background-color:#1a9851"|Phase III (E)
|Lapatinib<br> [[#Trastuzumab_monotherapy_2|Trastuzumab]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*NeoALTTO: [[Surgery#Breast_cancer_surgery|Surgery]], then [[Breast_cancer#FEC_2|adjuvant FEC]] x 3
====Chemotherapy====
*[[Lapatinib (Tykerb)]] 1000 mg PO once per day
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 8 mg/kg IV over 90 minutes once on day 1
**Cycles 2 to 12: 6 mg/kg IV over 30 minutes once on day 1

'''21-day cycle for 12 cycles (34-week course)'''

===References===
# '''NeoALTTO:''' Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horváth Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M; NeoALTTO Study Team. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012 Feb 18;379(9816):633-40. Epub 2012 Jan 17. Erratum in: Lancet. 2012 Feb 18;379(9816):616. Dosage error in published abstract; MEDLINE/PubMed abstract corrected. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61847-3/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705192/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22257673 PubMed]
## '''Update:''' de Azambuja E, Holmes AP, Piccart-Gebhart M, Holmes E, Di Cosimo S, Swaby RF, Untch M, Jackisch C, Lang I, Smith I, Boyle F, Xu B, Barrios CH, Perez EA, Azim HA Jr, Kim SB, Kuemmel S, Huang CS, Vuylsteke P, Hsieh RK, Gorbunova V, Eniu A, Dreosti L, Tavartkiladze N, Gelber RD, Eidtmann H, Baselga J. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol. 2014 Sep;15(10):1137-46. Epub 2014 Aug 14. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70320-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25130998 PubMed]
# '''ALTTO:''' Piccart-Gebhart M, Holmes E, Baselga J, de Azambuja E, Dueck AC, Viale G, Zujewski JA, Goldhirsch A, Armour A, Pritchard KI, McCullough AE, Dolci S, McFadden E, Holmes AP, Tonghua L, Eidtmann H, Dinh P, Di Cosimo S, Harbeck N, Tjulandin S, Im YH, Huang CS, Diéras V, Hillman DW, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Suter T, Gelber RD, Perez EA. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization trial. J Clin Oncol. 2016 Apr 1;34(10):1034-42. Epub 2015 Nov 23. [http://ascopubs.org/doi/full/10.1200/JCO.2015.62.1797 link to original article] [http://ascopubs.org/doi/suppl/10.1200/JCO.2015.62.1797/suppl_file/protocol_2015.621797.pdf link to protocol] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872016/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26598744 PubMed]

==Neratinib monotherapy {{#subobject:3c1a9c|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:d9f619|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00551-3/fulltext Chan et al. 2016 (ExteNET)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Placebo|Placebo]]
|style="background-color:#1a9850"|Superior invasive DFS
|-
|}
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]] and trastuzumab-containing chemotherapy (neoadjuvant or adjuvant)
====Chemotherapy====
*[[Neratinib (Nerlynx)]] 240 mg PO once per day, with food
====Supportive medications====
*(per FDA package insert)
*[[Loperamide (Imodium)]] as follows:
**Weeks 1 & 2: 4 mg PO TID
**Weeks 3 to 8: 4 mg PO twice per day
**Weeks 9 to 52: 4 mg PO as needed for diarrhea, not to exceed 16 mg/d

'''12-month course'''

===References===
# '''ExteNET:''' Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, Robert NJ, Silovski T, Gokmen E, von Minckwitz G, Ejlertsen B, Chia SK, Mansi J, Barrios CH, Gnant M, Buyse M, Gore I, Smith J 2nd, Harker G, Masuda N, Petrakova K, Zotano AG, Iannotti N, Rodriguez G, Tassone P, Wong A, Bryce R, Ye Y, Yao B, Martin M; ExteNET Study Group. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016 Mar;17(3):367-77. Epub 2016 Feb 10. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00551-3/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26874901 PubMed]
## '''Update:''' Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Dec;18(12):1688-1700. Epub 2017 Nov 13. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30717-9/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29146401 PubMed]

==Placebo==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00551-3/fulltext Chan et al. 2016 (ExteNET)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Neratinib_monotherapy|Neratinib]]
|style="background-color:#d73027"|Inferior invasive DFS
|-
|}
''No further treatment.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]] and trastuzumab-containing chemotherapy (neoadjuvant or adjuvant)

===References===
# '''ExteNET:''' Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, Robert NJ, Silovski T, Gokmen E, von Minckwitz G, Ejlertsen B, Chia SK, Mansi J, Barrios CH, Gnant M, Buyse M, Gore I, Smith J 2nd, Harker G, Masuda N, Petrakova K, Zotano AG, Iannotti N, Rodriguez G, Tassone P, Wong A, Bryce R, Ye Y, Yao B, Martin M; ExteNET Study Group. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016 Mar;17(3):367-77. Epub 2016 Feb 10. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00551-3/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26874901 PubMed]
## '''Update:''' Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Dec;18(12):1688-1700. Epub 2017 Nov 13. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30717-9/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29146401 PubMed]

==TCH (Taxotere, Carboplatin) {{#subobject:1b999b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
TCH: '''<u>T</u>'''axotere (Docetaxel), '''<u>C</u>'''arboplatin, '''<u>H</u>'''erceptin (Trastuzumab)
===Variant #1, capped carboplatin {{#subobject:99cbd0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538020/ von Minckwitz et al. 2017 (APHINITY)]
|style="background-color:#1a9851"|Phase III (C)
|[[#TCHP_.28Taxotere.29_2|TCHP (Taxotere)]] 
|style="background-color:#fc8d59"|Seems to have inferior invasive DFS
|-
|}
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Docetaxel (Taxotere)]] as follows:
**Cycles 1 to 6: 75 mg/m<sup>2</sup> IV once on day 1 
*[[Carboplatin (Paraplatin)]] as follows:
**Cycles 1 to 6: AUC 6 (maximum dose per cycle: 900 mg) IV once on day 1
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 8 mg/kg IV once on day 1
**Cycle 2 onwards: 6 mg/kg IV once on day 1

'''21-day cycle for up to 1 year of therapy (18 doses of trastuzumab)'''

===Variant #2, no cap {{#subobject:7a8d90|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3268553/ Slamon et al. 2011 (BCIRG 006)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[Breast_cancer#AC|AC]], then [[Breast_cancer#Docetaxel_monotherapy_2|T (Taxotere)]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|2. [[Breast_cancer#AC|AC]], then [[#TH_.28Taxotere.29_2|TH (Taxotere)]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872016/ Piccart-Gebhart et al. 2015 (ALTTO)]
|style="background-color:#1a9851"|Phase III (C)
|1. TCL (Taxotere)<br> 2. TCH (Taxotere), then Lapatinib<br> 3. TCHL (Taxotere)
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Docetaxel (Taxotere)]] as follows:
**Cycles 1 to 6: 75 mg/m<sup>2</sup> IV once on day 1 
*[[Carboplatin (Paraplatin)]] as follows:
**Cycles 1 to 6: AUC 6 IV once on day 1
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 4 mg/kg IV once on day 1, then 2 mg/kg IV once per day on days 8 & 15 
**Cycles 2 to 6: 2 mg/kg IV once per day on days 1, 8, 15
**Cycles 7 to 18: 6 mg/kg IV once on day 1

====Supportive medications====
*ALTTO: [[:Category:Granulocyte_colony-stimulating_factors|G-CSF]] use is mandatory (details not provided)

'''21-day cycle for 18 cycles'''

===References===
<!-- no pre-pub disclosed -->
# '''BCIRG 006:''' Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J; Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011 Oct 6;365(14):1273-83. [https://www.nejm.org/doi/full/10.1056/NEJMoa0910383 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3268553/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21991949 PubMed]
# '''APHINITY:''' von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017 Jul 13;377(2):122-131. Epub 2017 Jun 5. [https://www.nejm.org/doi/full/10.1056/NEJMoa1703643 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1703643/suppl_file/nejmoa1703643_protocol.pdf link to supplementary protocol] '''contains verified protocol in supplementary protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538020/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28581356 PubMed]
# '''ALTTO:''' Piccart-Gebhart M, Holmes E, Baselga J, de Azambuja E, Dueck AC, Viale G, Zujewski JA, Goldhirsch A, Armour A, Pritchard KI, McCullough AE, Dolci S, McFadden E, Holmes AP, Tonghua L, Eidtmann H, Dinh P, Di Cosimo S, Harbeck N, Tjulandin S, Im YH, Huang CS, Diéras V, Hillman DW, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Suter T, Gelber RD, Perez EA. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization trial. J Clin Oncol. 2016 Apr 1;34(10):1034-42. Epub 2015 Nov 23. [http://ascopubs.org/doi/full/10.1200/JCO.2015.62.1797 link to original article] [http://ascopubs.org/doi/suppl/10.1200/JCO.2015.62.1797/suppl_file/protocol_2015.621797.pdf link to protocol] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872016/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26598744 PubMed]

==TCH (Taxotere, Cyclophosphamide) {{#subobject:b0421b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
TCH: '''<u>T</u>'''axotere, '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''erceptin
===Regimen {{#subobject:d3aba1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2813%2970384-X/fulltext Jones et al. 2013]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]], within 84 days
====Chemotherapy====
*[[Docetaxel (Taxotere)]] as follows:
**Cycles 1 to 4: 75 mg/m<sup>2</sup> IV over 60 minutes once on day 1 
*[[Cyclophosphamide (Cytoxan)]] as follows:
**Cycles 1 to 4: 600 mg/m<sup>2</sup> IV over 15 to 30 minutes once on day 1
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 4 mg/kg IV over 90 minutes once on day 1, then 2 mg/kg IV over 30 to 60 minutes once per day on days 8 & 15
**Cycles 2 to 4: 2 mg/kg IV over 30 to 60 minutes once per day on days 1, 8, 15
**Cycles 6 to 18: 6 mg/kg IV once on day 1
====Supportive medications====
*Use of [[Filgrastim (Neupogen)]] or [[Pegfilgrastim (Neulasta)]] was allowed.
*Prophylactic antibiotics were not recommended.

'''21-day cycle for 18 cycles'''

===References===
# Jones SE, Collea R, Paul D, Sedlacek S, Favret AM, Gore I Jr, Lindquist DL, Holmes FA, Allison MA, Brooks BD, Portillo RM, Vukelja SJ, Steinberg MS, Stokoe C, Crockett MW, Wang Y, Asmar L, Robert NJ, O'Shaughnessy J. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study. Lancet Oncol. 2013 Oct;14(11):1121-8. Epub 2013 Sep 2. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2813%2970384-X/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24007746 PubMed]

==TCHP (Taxotere) {{#subobject:14bd42|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
TCHP: '''<u>T</u>'''axotere (Docetaxel), '''<u>C</u>'''arboplatin, '''<u>H</u>'''erceptin (Trastuzumab), '''<u>P</u>'''ertuzumab
===Regimen {{#subobject:34a874|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538020/ von Minckwitz et al. 2017 (APHINITY)]
|style="background-color:#1a9851"|Phase III (E)
|[[#TCH_.28Taxotere.2C_Carboplatin.29|TCH]] 
|style="background-color:#91cf60"|Seems to have superior invasive DFS
|-
|}
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Docetaxel (Taxotere)]] as follows:
**Cycles 1 to 6: 75 mg/m<sup>2</sup> IV once on day 1 
*[[Carboplatin (Paraplatin)]] as follows:
**Cycles 1 to 6: AUC 6 (maximum dose: 900 mg) IV once on day 1
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 8 mg/kg IV once on day 1
**Cycle 2 onwards: 6 mg/kg IV once on day 1
*[[Pertuzumab (Perjeta)]] as follows:
**Cycle 1: 840 mg IV once on day 1
**Cycle 2 onwards: 420 mg IV once on day 1

'''21-day cycle for up to 1 year of therapy (18 doses of trastuzumab & pertuzumab)'''

===References===
# '''APHINITY:''' von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017 Jul 13;377(2):122-131. Epub 2017 Jun 5. [https://www.nejm.org/doi/full/10.1056/NEJMoa1703643 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1703643/suppl_file/nejmoa1703643_protocol.pdf link to supplementary protocol] '''contains verified protocol in supplementary protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538020/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28581356 PubMed]

==TH (Taxol) {{#subobject:dc66e8|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
TH: '''<u>T</u>'''axol (Paclitaxel) & '''<u>H</u>'''erceptin (Trastuzumab)
<br> PH: '''<u>P</u>'''aclitaxel & '''<u>H</u>'''erceptin (Trastuzumab)
===Variant #1, weekly paclitaxel, weekly trastuzumab {{#subobject:PPV1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313867/ Tolaney et al. 2015 (APT)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV once per week on weeks 1 to 12
*[[Trastuzumab (Herceptin)]] as follows:
**Week 1: 4 mg/kg IV once on day 1 with the first dose of paclitaxel
**Weeks 2 to 52: 2 mg/kg IV once per week

'''12 weeks of paclitaxel, 52 weeks of trastuzumab'''

===Variant #2, weekly paclitaxel, weekly then q3wk trastuzumab {{#subobject:6e5b6d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313867/ Tolaney et al. 2015 (APT)]
|style="background-color:#91cf61"|Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872016/ Piccart-Gebhart et al. 2015 (ALTTO)]
|style="background-color:#1a9851"|Phase III (C)
|TH (Taxol), then Lapatinib<br> THL (Taxol)<br> TL (Taxol)
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Preceding treatment====
*APT: [[Surgery#Breast_cancer_surgery|Surgery]]
*ALTTO: [[Surgery#Breast_cancer_surgery|Surgery]], then anthracycline-based chemotherapy
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV once per week on weeks 1 to 12
*[[Trastuzumab (Herceptin)]] as follows:
**Week 1: 4 mg/kg IV once on day 1 with the first dose of paclitaxel
**Weeks 2 to 12: 2 mg/kg IV once per week
**Weeks 13 to 52: 6 mg/kg IV once every 3 weeks

'''12 weeks of paclitaxel, 52 weeks of trastuzumab'''

===Variant #3, weekly paclitaxel, q3wk trastuzumab {{#subobject:a4b465|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538020/ von Minckwitz et al. 2017 (APHINITY)]
|style="background-color:#1a9851"|Phase III (C)
|[[#THP_.28Taxol.29_2|THP (Taxol)]]
|style="background-color:#fc8d59"|Seems to have inferior invasive DFS
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[Breast_cancer#AC_2|AC]] x 4 or [[Breast_cancer#ddAC_2|ddAC]] x 4 or [[Breast_cancer#ddEC|ddEC]] x 4 or [[Breast_cancer#EC_2|EC]] x 4 or [[Breast_cancer#FAC|FAC]] x 4 or [[Breast_cancer#FEC_2|FEC]] x 4
====Chemotherapy====
*[[Paclitaxel (Taxol)]] as follows:
**Weeks 1 to 12: 80 mg/m<sup>2</sup> IV once per week
*[[Trastuzumab (Herceptin)]] as follows:
**Week 1: 8 mg/kg IV once on day 1
**Week 4 onwards: 6 mg/kg IV once every 3 weeks

'''Up to 1 year of therapy (18 doses of trastuzumab)'''

===Variant #4, q3wk paclitaxel, weekly trastuzumab {{#subobject:158d3d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa052122 Romond et al. 2005 (NSABP B-31)]
|style="background-color:#1a9851"|Phase III (E)
|[[Breast_cancer#Paclitaxel_monotherapy.2C_weekly_2|weekly T (Taxol)]]<br> [[Breast_cancer_-_historical#Paclitaxel_monotherapy.2C_q3wk|q3wk T (Taxol)]]
|style="background-color:#1a9850"|Superior OS
|style="background-color:#d9ef8b"|Might have superior DASI score
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa052122 Romond et al. 2005 (NCCTG N9831)]
|style="background-color:#1a9851"|Phase III (E)
|[[Complex_multipart_regimens#NCCTG_N9831|See link]]
|[[Complex_multipart_regimens#NCCTG_N9831|See link]]
|style="background-color:#d3d3d3"|
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[Breast_cancer#AC_2|AC]] x 4
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once per week on weeks 1, 4, 7, 10
*[[Trastuzumab (Herceptin)]] as follows:
**Week 1: 4 mg/kg IV once on day 1
**Weeks 2 to 52: 2 mg/kg IV once per week

'''4 cycles of paclitaxel, 52 weeks of trastuzumab'''

===References===
<!-- no pre-pub disclosed -->
# '''NSABP B-31/NCCTG N9831:''' Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005 Oct 20;353(16):1673-84. [https://www.nejm.org/doi/full/10.1056/NEJMoa052122 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16236738 PubMed]
## '''Update:''' Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr, Martino S, Mamounas EP, Kaufman PA, Wolmark N. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011 Sep 1;29(25):3366-73. Epub 2011 Jul 18. [http://ascopubs.org/doi/full/10.1200/JCO.2011.35.0868 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3164242/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21768458 PubMed]
## '''Update:''' Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW, Chen B, Ingle JN, Dakhil SR, Zujewski J, Moreno-Aspitia A, Pisansky TM, Jenkins RB. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol. 2011 Dec 1;29(34):4491-7. Epub 2011 Oct 31. [http://ascopubs.org/doi/full/10.1200/JCO.2011.36.7045 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236650/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22042958 PubMed]
## '''Update:''' Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr, Martino S, Rastogi P, Gralow J, Swain SM, Winer EP, Colon-Otero G, Davidson NE, Mamounas E, Zujewski JA, Wolmark N. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014 Nov 20;32(33):3744-52. [http://ascopubs.org/doi/full/10.1200/JCO.2014.55.5730 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226805/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25332249 PubMed]
## '''Update and HRQoL analysis:''' Ganz PA, Romond EH, Cecchini RS, Rastogi P, Geyer CE Jr, Swain SM, Jeong JH, Fehrenbacher L, Gross HM, Brufsky AM, Flynn PJ, Wahl TA, Seay TE, Wade JL 3rd, Biggs DD, Atkins JN, Polikoff J, Zapas JL, Mamounas EP, Wolmark N. Long-term follow-up of cardiac function and quality of life for patients in NSABP protocol B-31/NRG Oncology: a randomized trial comparing the safety and efficacy of doxorubicin and cyclophosphamide (AC) followed by paclitaxel with AC followed by paclitaxel and trastuzumab in patients with node-positive breast cancer with tumors overexpressing human epidermal growth factor receptor 2. J Clin Oncol. 2017 Dec 10;35(35):3942-3948. Epub 2017 Oct 26. [http://ascopubs.org/doi/full/10.1200/JCO.2017.74.1165 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721228/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/29072977 PubMed]
# '''CALGB 40101:''' Shulman LN, Cirrincione CT, Berry DA, Becker HP, Perez EA, O'Regan R, Martino S, Atkins JN, Mayer E, Schneider CJ, Kimmick G, Norton L, Muss H, Winer EP, Hudis C. Six Cycles of Doxorubicin and Cyclophosphamide or Paclitaxel Are Not Superior to Four Cycles As Adjuvant Chemotherapy for Breast Cancer in Women With Zero to Three Positive Axillary Nodes: Cancer and Leukemia Group B 40101. J Clin Oncol. 2012 Nov 20;30(33):4071-6. Epub 2012 Jul 23. [http://jco.ascopubs.org/content/30/33/4071.long link to original article] '''does not contain protocol''' [http://jco.ascopubs.org/content/suppl/2012/07/23/JCO.2011.40.6405.DC1/Protocol.pdf link to study protocol PDF] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494835/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22826271 PubMed]
## '''Update:''' Shulman LN, Berry DA, Cirrincione CT, Becker HP, Perez EA, O'Regan R, Martino S, Shapiro CL, Schneider CJ, Kimmick G, Burstein HJ, Norton L, Muss H, Hudis CA, Winer EP. Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). J Clin Oncol. 2014 Aug 1;32(22):2311-7. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4105484/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24934787 PubMed]
<!-- # '''Abstract:''' Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Guo H, Hudis CA, Krop IE, Burstein HJ, Winer EP. A phase II study of adjuvant paclitaxel and trastuzumab (APT trial) for node-negative, HER2-positive breast cancer. SABCS 2013, Abstract S1-04. [http://cancerres.aacrjournals.org/content/73/24_Supplement/S1-04.abstract link to abstract] -->
# '''APT:''' Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Guo H, Hudis CA, Krop IE, Burstein HJ, Winer EP. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015 Jan 8;372(2):134-41. Erratum in: N Engl J Med. 2015 Nov 12;373(20):1989. [https://www.nejm.org/doi/full/10.1056/NEJMoa1406281 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313867/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25564897 PubMed]
# '''ALTTO:''' Piccart-Gebhart M, Holmes E, Baselga J, de Azambuja E, Dueck AC, Viale G, Zujewski JA, Goldhirsch A, Armour A, Pritchard KI, McCullough AE, Dolci S, McFadden E, Holmes AP, Tonghua L, Eidtmann H, Dinh P, Di Cosimo S, Harbeck N, Tjulandin S, Im YH, Huang CS, Diéras V, Hillman DW, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Suter T, Gelber RD, Perez EA. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization trial. J Clin Oncol. 2016 Apr 1;34(10):1034-42. Epub 2015 Nov 23. [http://ascopubs.org/doi/full/10.1200/JCO.2015.62.1797 link to original article] [http://ascopubs.org/doi/suppl/10.1200/JCO.2015.62.1797/suppl_file/protocol_2015.621797.pdf link to protocol] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872016/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26598744 PubMed]
# '''APHINITY:''' von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017 Jul 13;377(2):122-131. Epub 2017 Jun 5. [https://www.nejm.org/doi/full/10.1056/NEJMoa1703643 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1703643/suppl_file/nejmoa1703643_protocol.pdf link to supplementary protocol] '''contains verified protocol in supplementary protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538020/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28581356 PubMed]

==TH (Taxotere) {{#subobject:a0af2c|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
TH: '''<u>T</u>'''axotere (Docetaxel) & '''<u>H</u>'''erceptin (Trastuzumab)
===Variant #1, 75 x 4, q3wk trastuzumab {{#subobject:2fb74a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538020/ von Minckwitz et al. 2017 (APHINITY)]
|style="background-color:#1a9851"|Phase III (C)
|[[#THP_.28Taxotere.29_2|THP (Taxotere)]]
|style="background-color:#fc8d59"|Seems to have inferior invasive DFS
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]], then [[Breast_cancer#AC_2|AC]] x 4 or [[Breast_cancer#ddAC_2|ddAC]] x 4 or [[Breast_cancer#ddEC|ddEC]] x 4 or [[Breast_cancer#EC_2|EC]] x 4 or [[Breast_cancer#FAC|FAC]] x 4 or [[Breast_cancer#FEC_2|FEC]] x 4
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 8 mg/kg IV once on day 1
**Cycles 2 to 4: 6 mg/kg IV once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[#Trastuzumab_monotherapy_2|Trastuzumab maintenance (q3wk)]] for a total of 1 year

===Variant #2, 75 x 4, weekly trastuzumab {{#subobject:5cbacf|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872016/ Piccart-Gebhart et al. 2015 (ALTTO)]
|style="background-color:#1a9851"|Phase III (C)
|TH (Taxotere), then Lapatinib<br> THL (Taxotere)<br> TL (Taxotere)
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]], then anthracycline-based chemotherapy
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 4 mg/kg IV once on day 1, then 2 mg/kg IV once per day on days 8 & 15
**Cycles 2 to 4: 2 mg/kg IV once per day on days 1, 8, 15

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[#Trastuzumab_monotherapy_2|Trastuzumab maintenance (q3wk)]] for a total of 1 year

===Variant #3, 75-100 x 3, q3wk trastuzumab {{#subobject:b884e0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538020/ von Minckwitz et al. 2017 (APHINITY)]
|style="background-color:#1a9851"|Phase III (C)
|[[#THP_.28Taxotere.29_2|THP (Taxotere)]]
|style="background-color:#fc8d59"|Seems to have inferior invasive DFS
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]], then [[Breast_cancer#AC_2|AC]] x 4 or [[Breast_cancer#ddAC_2|ddAC]] x 4 or [[Breast_cancer#ddEC|ddEC]] x 4 or [[Breast_cancer#EC_2|EC]] x 4 or [[Breast_cancer#FAC|FAC]] x 4 or [[Breast_cancer#FEC_2|FEC]] x 4
====Chemotherapy====
*[[Docetaxel (Taxotere)]] as follows:
**Cycle 1: 75 mg/m<sup>2</sup> IV once on day 1 
**Cycles 2 & 3: 100 mg/m<sup>2</sup> IV once on day 1
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 8 mg/kg IV once on day 1
**Cycle 2 onwards: 6 mg/kg IV once on day 1

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*[[#Trastuzumab_monotherapy_2|Trastuzumab maintenance (q3wk)]] for a total of 1 year

===Variant #4, 80 x 3, q3wk trastuzumab (IV) {{#subobject:481c04|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://jamanetwork.com/journals/jamaoncology/fullarticle/2682589 Joensuu et al. 2018 (SOLD)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 80 mg/m<sup>2</sup> IV once on day 1
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 8 mg/kg IV once on day 1
**Cycles 2 & 3: 6 mg/kg IV once on day 1

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*[[Breast_cancer#FEC_2|FEC]] x 3, then [[#Trastuzumab_monotherapy_2|trastuzumab maintenance]] for a total of 1 year versus no further treatment

===Variant #5, 80 x 3, q3wk trastuzumab (SC) {{#subobject:92b8bf|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://jamanetwork.com/journals/jamaoncology/fullarticle/2682589 Joensuu et al. 2018 (SOLD)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 80 mg/m<sup>2</sup> IV once on day 1
*[[Trastuzumab (Herceptin)]] 600 mg SC once on day 1

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*[[Breast_cancer#FEC_2|FEC]] x 3, then [[#Trastuzumab_monotherapy_2|trastuzumab maintenance]] for a total of 1 year versus no further treatment

===Variant #6, 80 x 3, weekly trastuzumab {{#subobject:f18df7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://jamanetwork.com/journals/jamaoncology/fullarticle/2682589 Joensuu et al. 2018 (SOLD)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 80 mg/m<sup>2</sup> IV once on day 1
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 4 mg/kg IV once on day 1, then 2 mg/kg IV once per day on days 8 & 15 
**Cycles 2 & 3: 2 mg/kg IV once per day on days 1, 8, 15

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*[[Breast_cancer#FEC_2|FEC]] x 3, then [[#Trastuzumab_monotherapy_2|trastuzumab maintenance]] for a total of 1 year versus no further treatment

===Variant #7, 100 x 3, q3wk trastuzumab (IV) {{#subobject:bea44d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538020/ von Minckwitz et al. 2017 (APHINITY)]
|style="background-color:#1a9851"|Phase III (C)
|[[#THP_.28Taxotere.29_2|THP (Taxotere)]]
|style="background-color:#fc8d59"|Seems to have inferior invasive DFS
|-
|[https://jamanetwork.com/journals/jamaoncology/fullarticle/2682589 Joensuu et al. 2018 (SOLD)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]], then [[Breast_cancer#AC_2|AC]] x 4 or [[Breast_cancer#ddAC_2|ddAC]] x 4 or [[Breast_cancer#ddEC|ddEC]] x 4 or [[Breast_cancer#EC_2|EC]] x 4 or [[Breast_cancer#FAC|FAC]] x 4 or [[Breast_cancer#FEC_2|FEC]] x 4
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 100 mg/m<sup>2</sup> IV once on day 1
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 8 mg/kg IV once on day 1
**Cycles 2 & 3: 6 mg/kg IV once on day 1

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*APHINITY: [[#Trastuzumab_monotherapy_2|Trastuzumab maintenance]] for a total of 1 year
*SOLD: [[Breast_cancer#FEC_2|FEC]] x 3, then [[#Trastuzumab_monotherapy_2|trastuzumab maintenance]] for a total of 1 year versus no further treatment

===Variant #8, 100 x 3, q3wk trastuzumab (SC) {{#subobject:eb48a0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://jamanetwork.com/journals/jamaoncology/fullarticle/2682589 Joensuu et al. 2018 (SOLD)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 100 mg/m<sup>2</sup> IV once on day 1
*[[Trastuzumab (Herceptin)]] 600 mg SC once on day 1

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*[[Breast_cancer#FEC_2|FEC]] x 3, then [[#Trastuzumab_monotherapy_2|trastuzumab maintenance]] for a total of 1 year versus no further treatment

===Variant #9, 100 x 3, weekly trastuzumab {{#subobject:8a1397|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[https://www.nejm.org/doi/full/10.1056/NEJMoa053028 Joensuu et al. 2006 (FinHer)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[Breast_cancer#Docetaxel_monotherapy_2|T]]<br> 2. [[Breast_cancer#Vinorelbine_monotherapy|V]]
|style="background-color:#ffffbf"|Seems not superior
|-
|3. [[#VH|VH]]
|style="background-color:#d3d3d3"|Not reported
|-
|[https://jamanetwork.com/journals/jamaoncology/fullarticle/2682589 Joensuu et al. 2018 (SOLD)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|}
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 100 mg/m<sup>2</sup> IV over 60 minutes once on day 1
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 4 mg/kg IV once on day 1, then 2 mg/kg IV once per day on days 8 & 15 
**Cycles 2 & 3: 2 mg/kg IV once per day on days 1, 8, 15

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*FinHer: [[Breast_cancer#FEC_2|FEC]]
*SOLD: [[Breast_cancer#FEC_2|FEC]] x 3, then [[#Trastuzumab_monotherapy_2|trastuzumab maintenance]] for a total of 1 year versus no further treatment

===Variant #10, 100 x 4, weekly trastuzumab {{#subobject:87716b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3268553/ Slamon et al. 2011 (BCIRG 006)]
|style="background-color:#1a9851"|Phase III (E)
|[[Complex_multipart_regimens#BCIRG_006|See link]]
|[[Complex_multipart_regimens#BCIRG_006|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]], then [[Breast_cancer#AC_2|AC]] x 4
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 100 mg/m<sup>2</sup> IV once on day 1
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 4 mg/kg IV once on day 1, then 2 mg/kg IV once per day on days 8 & 15
**Cycles 2 to 4: 2 mg/kg IV once per day on days 1, 8, 15

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[#Trastuzumab_monotherapy_2|Trastuzumab maintenance (q3wk)]] for a total of 1 year
===References===
<!-- no pre-pub disclosed -->
# '''FinHer:''' Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkiö S, Flander M, Helle L, Ingalsuo S, Johansson K, Jääskeläinen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J; FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006 Feb 23;354(8):809-20. [https://www.nejm.org/doi/full/10.1056/NEJMoa053028 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16495393 PubMed]
## '''Update:''' Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, Utriainen T, Turpeenniemi-Hujanen T, Jyrkkiö S, Möykkynen K, Helle L, Ingalsuo S, Pajunen M, Huusko M, Salminen T, Auvinen P, Leinonen H, Leinonen M, Isola J, Kellokumpu-Lehtinen PL. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: Final results of the FinHer trial. J Clin Oncol. 2009 Dec 1;27(34):5685-92. [http://ascopubs.org/doi/full/10.1200/JCO.2008.21.4577 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19884557 PubMed]
<!-- no pre-pub disclosed -->
# '''BCIRG 006:''' Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J; Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011 Oct 6;365(14):1273-83. [https://www.nejm.org/doi/full/10.1056/NEJMoa0910383 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3268553/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21991949 PubMed]
# '''ALTTO:''' Piccart-Gebhart M, Holmes E, Baselga J, de Azambuja E, Dueck AC, Viale G, Zujewski JA, Goldhirsch A, Armour A, Pritchard KI, McCullough AE, Dolci S, McFadden E, Holmes AP, Tonghua L, Eidtmann H, Dinh P, Di Cosimo S, Harbeck N, Tjulandin S, Im YH, Huang CS, Diéras V, Hillman DW, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Suter T, Gelber RD, Perez EA. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization trial. J Clin Oncol. 2016 Apr 1;34(10):1034-42. Epub 2015 Nov 23. [http://ascopubs.org/doi/full/10.1200/JCO.2015.62.1797 link to original article] [http://ascopubs.org/doi/suppl/10.1200/JCO.2015.62.1797/suppl_file/protocol_2015.621797.pdf link to protocol] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872016/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26598744 PubMed]
# '''APHINITY:''' von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017 Jul 13;377(2):122-131. Epub 2017 Jun 5. [https://www.nejm.org/doi/full/10.1056/NEJMoa1703643 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1703643/suppl_file/nejmoa1703643_protocol.pdf link to supplementary protocol] '''contains verified protocol in supplementary protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538020/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28581356 PubMed]
# '''SOLD:''' Joensuu H, Fraser J, Wildiers H, Huovinen R, Auvinen P, Utriainen M, Nyandoto P, Villman KK, Halonen P, Granstam-Björneklett H, Lundgren L, Sailas L, Turpeenniemi-Hujanen T, Tanner M, Yachnin J, Ritchie D, Johansson O, Huttunen T, Neven P, Canney P, Harvey VJ, Kellokumpu-Lehtinen PL, Lindman H. Effect of adjuvant trastuzumab for a duration of 9 weeks vs 1 year with concomitant chemotherapy for early human epidermal growth factor receptor 2-positive breast cancer: the SOLD randomized clinical trial. JAMA Oncol. 2018 Sep 1;4(9):1199-1206. [https://jamanetwork.com/journals/jamaoncology/fullarticle/2682589 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29852043 PubMed]

==THP (Taxol) {{#subobject:144d6f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
THP: '''<u>T</u>'''axol (Paclitaxel), '''<u>H</u>'''erceptin (Trastuzumab), '''<u>P</u>'''ertuzumab

===Regimen {{#subobject:fae5d9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538020/ von Minckwitz et al. 2017 (APHINITY)]
|style="background-color:#1a9851"|Phase III (E)
|[[#TH_.28Taxol.29_2|TH (Taxol)]]
|style="background-color:#91cf60"|Seems to have superior invasive DFS
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]], then [[Breast_cancer#AC_2|AC]] x 4 or [[Breast_cancer#ddAC_2|ddAC]] x 4 or [[Breast_cancer#ddEC|ddEC]] x 4 or [[Breast_cancer#EC_2|EC]] x 4 or [[Breast_cancer#FAC|FAC]] x 4 or [[Breast_cancer#FEC_2|FEC]] x 4
====Chemotherapy====
*[[Paclitaxel (Taxol)]] as follows:
**Weeks 1 to 12: 80 mg/m<sup>2</sup> IV once per week
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 8 mg/kg IV once on day 1
**Cycle 2 onwards: 6 mg/kg IV once on day 1
*[[Pertuzumab (Perjeta)]] as follows:
**Cycle 1: 840 mg IV once on day 1
**Cycle 2 onwards: 420 mg IV once on day 1

'''21-day cycle for up to 1 year of therapy (18 doses of trastuzumab)'''

===References===
# '''APHINITY:''' von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017 Jul 13;377(2):122-131. Epub 2017 Jun 5. [https://www.nejm.org/doi/full/10.1056/NEJMoa1703643 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1703643/suppl_file/nejmoa1703643_protocol.pdf link to supplementary protocol] '''contains verified protocol in supplementary protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538020/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28581356 PubMed]

==THP (Taxotere) {{#subobject:2e09e0|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
THP: '''<u>T</u>'''axotere (Docetaxel), '''<u>H</u>'''erceptin (Trastuzumab), '''<u>P</u>'''ertuzumab
===Variant #1 {{#subobject:04d21a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538020/ von Minckwitz et al. 2017 (APHINITY)]
|style="background-color:#1a9851"|Phase III (E)
|[[#TH_.28Taxotere.29_2|TH (Taxotere)]]
|style="background-color:#91cf60"|Seems to have superior invasive DFS
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]], then [[Breast_cancer#AC_2|AC]] x 4 or [[Breast_cancer#ddAC_2|ddAC]] x 4 or [[Breast_cancer#ddEC|ddEC]] x 4 or [[Breast_cancer#EC_2|EC]] x 4 or [[Breast_cancer#FAC|FAC]] x 4 or [[Breast_cancer#FEC_2|FEC]] x 4
====Chemotherapy====
*[[Docetaxel (Taxotere)]] as follows:
**Cycles 1 to 3: 100 mg/m<sup>2</sup> IV once on day 1
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 8 mg/kg IV once on day 1
**Cycle 2 onwards: 6 mg/kg IV once on day 1
*[[Pertuzumab (Perjeta)]] as follows:
**Cycle 1: 840 mg IV once on day 1
**Cycle 2 onwards: 420 mg IV once on day 1

'''21-day cycle for up to 1 year of therapy (18 doses of trastuzumab)'''

===Variant #2 {{#subobject:43cff1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538020/ von Minckwitz et al. 2017 (APHINITY)]
|style="background-color:#1a9851"|Phase III (E)
|[[#TH_.28Taxotere.29_2|TH (Taxotere)]]
|style="background-color:#91cf60"|Seems to have superior invasive DFS
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]], then [[Breast_cancer#AC_2|AC]] x 4 or [[Breast_cancer#ddAC_2|ddAC]] x 4 or [[Breast_cancer#ddEC|ddEC]] x 4 or [[Breast_cancer#EC_2|EC]] x 4 or [[Breast_cancer#FAC|FAC]] x 4 or [[Breast_cancer#FEC_2|FEC]] x 4
====Chemotherapy====
*[[Docetaxel (Taxotere)]] as follows:
**Cycle 1: 75 mg/m<sup>2</sup> IV once on day 1 
**Cycles 2 & 3: 100 mg/m<sup>2</sup> IV once on day 1
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 8 mg/kg IV once on day 1
**Cycle 2 onwards: 6 mg/kg IV once on day 1
*[[Pertuzumab (Perjeta)]] as follows:
**Cycle 1: 840 mg IV once on day 1
**Cycle 2 onwards: 420 mg IV once on day 1

'''21-day cycle for up to 1 year of therapy (18 doses of trastuzumab)'''

===Variant #3 {{#subobject:db9cfb|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538020/ von Minckwitz et al. 2017 (APHINITY)]
|style="background-color:#1a9851"|Phase III (E)
|[[#TH_.28Taxotere.29_2|TH (Taxotere)]]
|style="background-color:#91cf60"|Seems to have superior invasive DFS
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]], then [[Breast_cancer#AC_2|AC]] x 4 or [[Breast_cancer#ddAC_2|ddAC]] x 4 or [[Breast_cancer#ddEC|ddEC]] x 4 or [[Breast_cancer#EC_2|EC]] x 4 or [[Breast_cancer#FAC|FAC]] x 4 or [[Breast_cancer#FEC_2|FEC]] x 4
====Chemotherapy====
*[[Docetaxel (Taxotere)]] as follows:
**Cycles 1 to 4: 75 mg/m<sup>2</sup> IV once on day 1
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 8 mg/kg IV once on day 1
**Cycle 2 onwards: 6 mg/kg IV once on day 1
*[[Pertuzumab (Perjeta)]] as follows:
**Cycle 1: 840 mg IV once on day 1
**Cycle 2 onwards: 420 mg IV once on day 1

'''21-day cycle for up to 1 year of therapy (18 doses of trastuzumab)'''

===References===
# '''APHINITY:''' von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017 Jul 13;377(2):122-131. Epub 2017 Jun 5. [https://www.nejm.org/doi/full/10.1056/NEJMoa1703643 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1703643/suppl_file/nejmoa1703643_protocol.pdf link to supplementary protocol] '''contains verified protocol in supplementary protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538020/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28581356 PubMed]

==Trastuzumab monotherapy {{#subobject:e585d5|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 30-week course, q3wk {{#subobject:057a24|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2017.74.0126 Pivot et al. 2018 (SB3-G31-BC)]
|style="background-color:#1a9851"|Phase III (C)
|[[Complex_multipart_regimens#SB3-G31-BC|See link]]
|[[Complex_multipart_regimens#SB3-G31-BC|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[#TH_.28Taxotere.29|Neoadjuvant TH (Taxotere)]] x 4, then [[#FEC_.26_H|FEC & H]] x 4, then [[Surgery#Breast_cancer_surgery|surgery]]
====Chemotherapy====
*[[Trastuzumab (Herceptin)]] 6 mg/kg IV over 30 minutes once on day 1

'''21-day cycle for 10 cycles (30-week course)'''

===Variant #2, 34-week course, q3wk {{#subobject:aa250f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61847-3/fulltext Baselga et al. 2012 (NeoALTTO)]
|style="background-color:#1a9851"|Phase III (C)
|[[Complex_multipart_regimens#NeoALTTO|See link]]
|[[Complex_multipart_regimens#NeoALTTO|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]], then [[Breast_cancer#FEC_2|adjuvant FEC]] x 3
====Chemotherapy====
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 8 mg/kg IV over 90 minutes once on day 1
**Cycles 2 to 12: 6 mg/kg IV over 30 minutes once on day 1

'''21-day cycle for 12 cycles (34-week course)'''

===Variant #3, 1-year course, weekly {{#subobject:9a3cba|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pubmed/14715110 Van Pelt et al. 2003]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa052122 Romond et al. 2005 (NCCTG N9831)]
|style="background-color:#1a9851"|Phase III (E)
|[[Complex_multipart_regimens#NCCTG_N9831|See link]]
|[[Complex_multipart_regimens#NCCTG_N9831|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment. '''Van Pelt et al. 2003''' does not describe a loading dose (in the abstract).''
====Preceding treatment====
*Van Pelt et al. 2003: [[Breast_cancer#AC_2|AC]] x 4
*NCCTG N9831: [[Breast_cancer#Paclitaxel_monotherapy.2C_weekly_2|weekly T]] x 12

====Chemotherapy====
*[[Trastuzumab (Herceptin)]] 4 mg/kg IV loading dose, then 2 mg/kg IV once per week

'''52-week course'''

===Variant #4, 1-year total course, q3wk (IV) {{#subobject:857980|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[https://www.nejm.org/doi/full/10.1056/NEJMoa052306 Piccart-Gebhart et al. 2005 (HERA)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. No trastuzumab after (neo-)adjuvant chemotherapy
|style="background-color:#1a9850"|Superior OS
|-
|2. Trastuzumab x 2 y
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61964-4/fulltext Gianni et al. 2010 (NOAH)]
|style="background-color:#1a9851"|Phase III (E)
|[[Complex_multipart_regimens#NOAH|See link]]
| style="background-color:#91cf60" |[[Complex_multipart_regimens#NOAH|See link]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70225-0/fulltext Pivot et al. 2013 (PHARE)]
|style="background-color:#1a9851"|Phase III (C)
|Trastuzumab x 6 mo
|style="background-color:#ffffbf"|Inconclusive whether non-inferior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872016/ Piccart-Gebhart et al. 2015 (ALTTO)]
|style="background-color:#1a9851"|Phase III (C)
|Lapatinib<br> Trastuzumab, then Lapatinib<br> [[#Lapatinib_.26_Trastuzumab_2|Lapatinib & Trastuzumab]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://jamanetwork.com/journals/jamaoncology/fullarticle/2682589 Joensuu et al. 2018 (SOLD)]
|style="background-color:#1a9851"|Phase III (C)
|No further treatment
|style="background-color:#ffffbf"|Inconclusive whether non-inferior
|-
|[https://academic.oup.com/annonc/article/29/12/2328/5096775 Conte et al. 2018 (Short-HER)]
|style="background-color:#1a9851"|Phase III (C)
|Trastuzumab x 9 wks total
|style="background-color:#ffffbf"|Inconclusive whether non-inferior
|-
|}
''Note: for patients already receiving trastuzumab prior to transitioning to monotherapy, re-loading is not necessary.''
====Preceding treatment====
*Participants had already received at least four courses of an approved (neo-)adjuvant chemotherapy regimen and [[Surgery#Breast_cancer_surgery|surgery]] (see individual trials)
*SOLD: [[Surgery#Breast_cancer_surgery|Surgery]], then [[#TH_.28Taxotere.29_2|TH (Taxotere)]] x 3, then [[Breast_cancer#FEC_2|FEC]] x 3
*Short-HER:  [[Surgery#Breast_cancer_surgery|Surgery]], then [[Breast_cancer#AC_2|AC]] or [[Breast_cancer#EC_2|EC]] x 4, then [[#TH_.28Taxol.29_2|TH (Taxol)]] or [[#TH_.28Taxotere.29_2|TH (Taxotere)]]
====Chemotherapy====
*[[Trastuzumab (Herceptin)]] as follows (see note):
**Cycle 1: 8 mg/kg IV over 90 minutes once on day 1
**Cycle 2 onwards: 6 mg/kg IV over 90 minutes once on day 1

'''21-day cycles for 1 year'''

===Variant #5, 1-year total course, q3wk (SC) {{#subobject:0cc6c6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://jamanetwork.com/journals/jamaoncology/fullarticle/2682589 Joensuu et al. 2018 (SOLD)]
|style="background-color:#1a9851"|Phase III (C)
|No further treatment
|style="background-color:#ffffbf"|Inconclusive whether non-inferior
|-
|}
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]], then [[#TH_.28Taxotere.29_2|TH (Taxotere)]] x 3, then [[Breast_cancer#FEC_2|FEC]] x 3
====Chemotherapy====
*[[Trastuzumab (Herceptin)]] 600 mg SC once on day 1

'''21-day cycles for 1 year'''

===Variant #6, 2-year course {{#subobject:2e0aa2|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[https://www.nejm.org/doi/full/10.1056/NEJMoa052306 Piccart-Gebhart et al. 2005 (HERA)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. No trastuzumab after (neo-)adjuvant chemotherapy
|style="background-color:#d3d3d3"|Not reported
|-
|2. Trastuzumab x 1 y
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Preceding treatment====
*Participants had already received at least four courses of an approved (neo-)adjuvant chemotherapy regimen and [[Surgery#Breast_cancer_surgery|surgery]]
====Chemotherapy====
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 8 mg/kg IV over 90 minutes once on day 1
**Cycle 2 onwards: 6 mg/kg IV over 90 minutes once on day 1

'''21-day cycles for 2 years'''

===References===
# Van Pelt AE, Mohsin S, Elledge RM, Hilsenbeck SG, Gutierrez MC, Lucci A Jr, Kalidas M, Granchi T, Scott BG, Allred DC, Chang JC. Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin Breast Cancer. 2003 Dec;4(5):348-53. [https://www.ncbi.nlm.nih.gov/pubmed/14715110 PubMed]
# '''HERA:''' Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005 Oct 20;353(16):1659-72. [https://www.nejm.org/doi/full/10.1056/NEJMoa052306 link to original article] '''contains verified protocol''' [https://www.nejm.org/doi/suppl/10.1056/NEJMoa052306/suppl_file/nejm_piccart_1659sa1-2.pdf link to data supplement]] [https://www.ncbi.nlm.nih.gov/pubmed/16236737 PubMed]
## '''Update:''' Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sánchez Rovira P, Piccart-Gebhart MJ; HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007 Jan 6;369(9555):29-36. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(07)60028-2/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17208639 PubMed]
## '''Update:''' Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, Untch M, Smith I, Baselga J, Jackisch C, Cameron D, Mano M, Pedrini JL, Veronesi A, Mendiola C, Pluzanska A, Semiglazov V, Vrdoljak E, Eckart MJ, Shen Z, Skiadopoulos G, Procter M, Pritchard KI, Piccart-Gebhart MJ, Bell R; Herceptin Adjuvant (HERA) Trial Study Team. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011 Mar;12(3):236-44. Epub 2011 Feb 25. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70033-X/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21354370 PubMed]
## '''Update:''' Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, de Azambuja E, Procter M, Suter TM, Jackisch C, Cameron D, Weber HA, Heinzmann D, Dal Lago L, McFadden E, Dowsett M, Untch M, Gianni L, Bell R, Köhne CH, Vindevoghel A, Andersson M, Brunt AM, Otero-Reyes D, Song S, Smith I, Leyland-Jones B, Baselga J; Herceptin Adjuvant (HERA) Trial Study Team. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet. 2013 Sep 21;382(9897):1021-8. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)61094-6/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23871490 PubMed]
## '''Update:''' Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, Castro G Jr, Untch M, Smith I, Gianni L, Baselga J, Al-Sakaff N, Lauer S, McFadden E, Leyland-Jones B, Bell R, Dowsett M, Jackisch C; Herceptin Adjuvant (HERA) Trial Study Team. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017 Mar 25;389(10075):1195-1205. Epub 2017 Feb 17. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)32616-2/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5465633/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28215665 PubMed]
<!-- no pre-pub disclosed -->
# '''NCCTG N9831:''' Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005 Oct 20;353(16):1673-84. [https://www.nejm.org/doi/full/10.1056/NEJMoa052122 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16236738 PubMed]
## '''Update:''' Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr, Martino S, Mamounas EP, Kaufman PA, Wolmark N. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011 Sep 1;29(25):3366-73. Epub 2011 Jul 18. [http://ascopubs.org/doi/full/10.1200/JCO.2011.35.0868 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3164242/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21768458 PubMed]
## '''Update:''' Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW, Chen B, Ingle JN, Dakhil SR, Zujewski J, Moreno-Aspitia A, Pisansky TM, Jenkins RB. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol. 2011 Dec 1;29(34):4491-7. Epub 2011 Oct 31. [http://ascopubs.org/doi/full/10.1200/JCO.2011.36.7045 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236650/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22042958 PubMed]
## '''Update:''' Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr, Martino S, Rastogi P, Gralow J, Swain SM, Winer EP, Colon-Otero G, Davidson NE, Mamounas E, Zujewski JA, Wolmark N. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014 Nov 20;32(33):3744-52. [http://ascopubs.org/doi/full/10.1200/JCO.2014.55.5730 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226805/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25332249 PubMed]
# '''NOAH:''' Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhow M, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Baronio R, Feyereislova A, Barton C, Valagussa P, Baselga J. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010 Jan 30;375(9712):377-84. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61964-4/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20113825 PubMed]
## '''Update:''' Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, Zambetti M, Moliterni A, Vazquez F, Byakhov MJ, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Magazzù D, Heinzmann D, Steinseifer J, Valagussa P, Baselga J. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol. 2014 May;15(6):640-7. Epub 2014 Mar 20. Erratum in: Lancet Oncol. 2018 Dec;19(12):e667. [https://www.sciencedirect.com/science/article/pii/S1470204514700804 link to SD article] [https://www.ncbi.nlm.nih.gov/pubmed/24657003 PubMed]
# '''NeoALTTO:''' Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horváth Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M; NeoALTTO Study Team. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012 Feb 18;379(9816):633-40. Epub 2012 Jan 17. Erratum in: Lancet. 2012 Feb 18;379(9816):616. Dosage error in published abstract; MEDLINE/PubMed abstract corrected. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61847-3/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705192/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22257673 PubMed]
## '''Update:''' de Azambuja E, Holmes AP, Piccart-Gebhart M, Holmes E, Di Cosimo S, Swaby RF, Untch M, Jackisch C, Lang I, Smith I, Boyle F, Xu B, Barrios CH, Perez EA, Azim HA Jr, Kim SB, Kuemmel S, Huang CS, Vuylsteke P, Hsieh RK, Gorbunova V, Eniu A, Dreosti L, Tavartkiladze N, Gelber RD, Eidtmann H, Baselga J. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol. 2014 Sep;15(10):1137-46. Epub 2014 Aug 14. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70320-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25130998 PubMed]
# '''CALGB 40101:''' Shulman LN, Cirrincione CT, Berry DA, Becker HP, Perez EA, O'Regan R, Martino S, Atkins JN, Mayer E, Schneider CJ, Kimmick G, Norton L, Muss H, Winer EP, Hudis C. Six Cycles of Doxorubicin and Cyclophosphamide or Paclitaxel Are Not Superior to Four Cycles As Adjuvant Chemotherapy for Breast Cancer in Women With Zero to Three Positive Axillary Nodes: Cancer and Leukemia Group B 40101. J Clin Oncol. 2012 Nov 20;30(33):4071-6. Epub 2012 Jul 23. [http://ascopubs.org/doi/full/10.1200/JCO.2011.40.6405 link to original article] '''contains verified protocol''' [http://ascopubs.org/doi/suppl/10.1200/jco.2011.40.6405/suppl_file/Protocol.pdf link to study protocol PDF] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494835/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22826271 PubMed]
## '''Update:''' Shulman LN, Berry DA, Cirrincione CT, Becker HP, Perez EA, O'Regan R, Martino S, Shapiro CL, Schneider CJ, Kimmick G, Burstein HJ, Norton L, Muss H, Hudis CA, Winer EP. Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). J Clin Oncol. 2014 Aug 1;32(22):2311-7. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4105484/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24934787 PubMed]
# '''PHARE:''' Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Tubiana-Mathieu N, Cany L, Catala S, Khayat D, Pauporté I, Kramar A; PHARE trial investigators. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol. 2013 Jul;14(8):741-8. Epub 2013 Jun 11. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70225-0/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23764181 PubMed]
# '''NSABP B-41:''' Robidoux A, Tang G, Rastogi P, Geyer CE Jr, Azar CA, Atkins JN, Fehrenbacher L, Bear HD, Baez-Diaz L, Sarwar S, Margolese RG, Farrar WB, Brufsky AM, Shibata HR, Bandos H, Paik S, Costantino JP, Swain SM, Mamounas EP, Wolmark N. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol. 2013 Nov;14(12):1183-92. Epub 2013 Oct 4. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70411-X/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24095300 PubMed]
# '''HORG CT/04.23:''' Mavroudis D, Saloustros E, Malamos N, Kakolyris S, Boukovinas I, Papakotoulas P, Kentepozidis N, Ziras N, Georgoulias V; Breast Cancer Investigators of Hellenic Oncology Research Group (HORG). Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). Ann Oncol. 2015 Jul;26(7):1333-40. Epub 2015 May 1. [https://academic.oup.com/annonc/article/26/7/1333/165655 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25935793 PubMed]
# '''ALTTO:''' Piccart-Gebhart M, Holmes E, Baselga J, de Azambuja E, Dueck AC, Viale G, Zujewski JA, Goldhirsch A, Armour A, Pritchard KI, McCullough AE, Dolci S, McFadden E, Holmes AP, Tonghua L, Eidtmann H, Dinh P, Di Cosimo S, Harbeck N, Tjulandin S, Im YH, Huang CS, Diéras V, Hillman DW, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Suter T, Gelber RD, Perez EA. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization trial. J Clin Oncol. 2016 Apr 1;34(10):1034-42. Epub 2015 Nov 23. [http://ascopubs.org/doi/full/10.1200/JCO.2015.62.1797 link to original article] [http://ascopubs.org/doi/suppl/10.1200/JCO.2015.62.1797/suppl_file/protocol_2015.621797.pdf link to protocol] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872016/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26598744 PubMed]
# '''SB3-G31-BC:''' Pivot X, Bondarenko I, Nowecki Z, Dvorkin M, Trishkina E, Ahn JH, Vinnyk Y, Im SA, Sarosiek T, Chatterjee S, Wojtukiewicz MZ, Moiseyenko V, Shparyk Y, Bello M 3rd, Semiglazov V, Song S, Lim J. Phase III, randomized, double-blind study comparing the efficacy, safety, and immunogenicity of SB3 (trastuzumab biosimilar) and reference trastuzumab in patients treated with neoadjuvant therapy for human epidermal growth factor receptor 2-positive early breast cancer. J Clin Oncol. 2018 Apr 1;36(10):968-974. Epub 2018 Jan 26. [http://ascopubs.org/doi/full/10.1200/JCO.2017.74.0126 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29373094 PubMed]
# '''SOLD:''' Joensuu H, Fraser J, Wildiers H, Huovinen R, Auvinen P, Utriainen M, Nyandoto P, Villman KK, Halonen P, Granstam-Björneklett H, Lundgren L, Sailas L, Turpeenniemi-Hujanen T, Tanner M, Yachnin J, Ritchie D, Johansson O, Huttunen T, Neven P, Canney P, Harvey VJ, Kellokumpu-Lehtinen PL, Lindman H. Effect of adjuvant trastuzumab for a duration of 9 weeks vs 1 year with concomitant chemotherapy for early human epidermal growth factor receptor 2-positive breast cancer: the SOLD randomized clinical trial. JAMA Oncol. 2018 Sep 1;4(9):1199-1206. [https://jamanetwork.com/journals/jamaoncology/fullarticle/2682589 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29852043 PubMed]
# '''Short-HER:''' Conte P, Frassoldati A, Bisagni G, Brandes AA, Donadio M, Garrone O, Piacentini F, Cavanna L, Giotta F, Aieta M, Gebbia V, Molino A, Musolino A, Ferro A, Maltoni R, Danese S, Zamagni C, Rimanti A, Cagossi K, Russo A, Pronzato P, Giovanardi F, Moretti G, Lombardo L, Schirone A, Beano A, Amaducci L, Bajardi EA, Vicini R, Balduzzi S, D'Amico R, Guarneri V; Reader study level-I and level-II Groups . Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. Ann Oncol. 2018 Dec 1;29(12):2328-2333. [https://academic.oup.com/annonc/article/29/12/2328/5096775 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/30219886 PubMed]

==T-DM1 monotherapy {{#subobject:d150e0|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
T-DM1: '''<u>T</u>'''rastuzumab-'''<u>DM1</u>''' (ado-Trastuzumab emtansine)
===Example orders===
*[[Example orders for Ado-trastuzumab emtansine (Kadcyla) in breast cancer]]

===Regimen {{#subobject:d31a82|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1814017 von Minckwitz et al. 2018 (KATHERINE)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Trastuzumab_monotherapy_2|Trastuzumab]]
|style="background-color:#1a9850"|Superior OS
|-
|}
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]], with residual invasive disease
====Chemotherapy====
*[[Ado-trastuzumab emtansine (Kadcyla)]] 3.6 mg/kg IV once on day 1

'''21-day cycle for 14 cycles'''

===References===
# '''KATHERINE:''' von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr; KATHERINE Investigators. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2018 Dec 5. [Epub ahead of print] [https://www.nejm.org/doi/full/10.1056/NEJMoa1814017 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/30516102 PubMed]

==VH {{#subobject:ca8dff|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
VH: '''<u>V</u>'''inorelbine & '''<u>H</u>'''erceptin (Trastuzumab)

===Regimen {{#subobject:f78da8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[https://www.nejm.org/doi/full/10.1056/NEJMoa053028 Joensuu et al. 2006 (FinHer)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[Breast_cancer#Docetaxel_monotherapy_2|T]]<br> 2. [[Breast_cancer#Vinorelbine_monotherapy|V]]
|style="background-color:#ffffbf"|Seems not superior
|-
|3. [[#TH_.28Taxotere.29_2|TH (Taxotere)]] 
|style="background-color:#d3d3d3"|Not reported
|-
|}
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Vinorelbine (Navelbine)]] 24 mg/m<sup>2</sup> IV over 5 to 10 minutes once per day on days 1, 8, 15
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 4 mg/kg IV once on day 1, then 2 mg/kg IV once per day on days 8 & 15
**Cycles 2 & 3: 2 mg/kg IV once per day on days 1, 8, 15

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*[[Breast_cancer#FEC_2|FEC]]
===References===
<!-- no pre-pub disclosed -->
# Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkiö S, Flander M, Helle L, Ingalsuo S, Johansson K, Jääskeläinen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J; FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006 Feb 23;354(8):809-20. [https://www.nejm.org/doi/full/10.1056/NEJMoa053028 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16495393 PubMed]
## '''Update:''' Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, Utriainen T, Turpeenniemi-Hujanen T, Jyrkkiö S, Möykkynen K, Helle L, Ingalsuo S, Pajunen M, Huusko M, Salminen T, Auvinen P, Leinonen H, Leinonen M, Isola J, Kellokumpu-Lehtinen PL. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol. 2009 Dec 1;27(34):5685-92. [http://ascopubs.org/doi/full/10.1200/JCO.2008.21.4577 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19884557 PubMed]

=Metastatic or unresectable disease, first-line=
''Note: some patients in these trials were pre-treated with non-HER2-targeted therapies.''
==ACH {{#subobject:92e436|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ACH: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''erceptin (Trastuzumab)

===Regimen {{#subobject:67e482|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM200103153441101 Slamon et al. 2001]
|style="background-color:#1a9851"|Phase III (E)
|[[Breast_cancer#AC_2|AC]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
''Note: patients had not previously received adjuvant (postoperative) therapy with an anthracycline. Not commonly used; here for reference purposes only.''
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 
*[[Cyclophosphamide (Cytoxan)]] 
*[[Trastuzumab (Herceptin)]]

===References===
# Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar 15;344(11):783-92. [https://www.nejm.org/doi/full/10.1056/NEJM200103153441101 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11248153 PubMed]

==Capecitabine, Bevacizumab, Trastuzumab {{#subobject:b68b8e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:d76d98|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!Study
![[Levels_of_Evidence#Evidence|Evidence]]
|[[Levels_of_Evidence#Evidence|'''Efficacy''']]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3336828/ Martín et al. 2012]
|style="background-color:#91cf61"|Phase II
|style="background-color:#bababa"|ORR: 73% (95% CI 62-82)
|-
|}
====Chemotherapy====
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1
*[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 8 mg/kg IV once on day 1
**Cycle 2 onwards: 6 mg/kg IV once on day 1

'''21-day cycles'''

===References===
# Martín M, Makhson A, Gligorov J, Lichinitser M, Lluch A, Semiglazov V, Scotto N, Mitchell L, Tjulandin S. Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer. Oncologist. 2012;17(4):469-75. Epub 2012 Mar 30. [http://theoncologist.alphamedpress.org/content/17/4/469.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3336828/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22467666 PubMed]

==Capecitabine & Lapatinib {{#subobject:800fde|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:653bef|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2014.57.1794 Pivot et al. 2015 (CEREBEL)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Capecitabine_.26_Trastuzumab|Capecitabine & Trastuzumab]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: the primary endpoint of CEREBEL was incidence of CNS as site of first relapse; this was very low in both arms, with no statistically significant difference.''
====Chemotherapy====
*[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14
*[[Lapatinib (Tykerb)]] 1250 mg PO once per day

'''21-day cycles'''

===References===
# '''CEREBEL:''' Pivot X, Manikhas A, Żurawski B, Chmielowska E, Karaszewska B, Allerton R, Chan S, Fabi A, Bidoli P, Gori S, Ciruelos E, Dank M, Hornyak L, Margolin S, Nusch A, Parikh R, Nagi F, DeSilvio M, Santillana S, Swaby RF, Semiglazov V. CEREBEL (EGF111438): A phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2015 May 10;33(14):1564-73. Epub 2015 Jan 20. [http://ascopubs.org/doi/full/10.1200/JCO.2014.57.1794 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25605838 PubMed]

==Capecitabine & Trastuzumab {{#subobject:677608|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
XH: '''<u>X</u>'''eloda (Capecitabine) & '''<u>H</u>'''erceptin
===Regimen {{#subobject:e14cab|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2014.57.1794 Pivot et al. 2015 (CEREBEL)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Capecitabine_.26_Lapatinib|Capecitabine & Lapatanib]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: the primary endpoint of CEREBEL was incidence of CNS as site of first relapse; this was very low in both arms, with no statistically significant difference.''
====Chemotherapy====
*[[Capecitabine (Xeloda)]] 1250 mg/m<sup>2</sup> PO twice per day on days 1 to 14
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 8 mg/kg IV once on day 1
**Cycle 2 onwards: 6 mg/kg IV once on day 1

'''21-day cycles'''

===References===
# '''CEREBEL:''' Pivot X, Manikhas A, Żurawski B, Chmielowska E, Karaszewska B, Allerton R, Chan S, Fabi A, Bidoli P, Gori S, Ciruelos E, Dank M, Hornyak L, Margolin S, Nusch A, Parikh R, Nagi F, DeSilvio M, Santillana S, Swaby RF, Semiglazov V. CEREBEL (EGF111438): A phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2015 May 10;33(14):1564-73. Epub 2015 Jan 20. [http://ascopubs.org/doi/full/10.1200/JCO.2014.57.1794 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25605838 PubMed]

==ECH {{#subobject:fd17f7|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ECH: '''<u>E</u>'''pirubicin, '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''erceptin (Trastuzumab)

===Regimen {{#subobject:959eb9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM200103153441101 Slamon et al. 2001]
|style="background-color:#1a9851"|Phase III (E)
|[[Breast_cancer#EC_3|EC]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
''Not commonly used; here for reference purposes only.''
====Chemotherapy====
*[[Epirubicin (Ellence)]] 
*[[Cyclophosphamide (Cytoxan)]]
*[[Trastuzumab (Herceptin)]]

===References===
# Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar 15;344(11):783-92. [https://www.nejm.org/doi/full/10.1056/NEJM200103153441101 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11248153 PubMed]

==Pertuzumab & T-DM1 {{#subobject:ffffbc|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
Pertuzumab & T-DM1: Pertuzumab & '''<u>T</u>'''rastuzumab-'''<u>DM1</u>''' (ado-Trastuzumab emtansine)
===Regimen {{#subobject:c8ce38|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455677/ Perez et al. 2016 (MARIANNE)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#T-DM1_monotherapy_3|T-DM1]]
|style="background-color:#eeee01"|Non-inferior PFS
|-
|2. [[#TH_.28Taxotere.29_3|TH (Taxotere)]]<br> 3. [[#TH_.28Taxol.29_3|TH (Taxol)]]
|style="background-color:#eeee01"|Non-inferior PFS
|-
|}
====Chemotherapy====
*[[Pertuzumab (Perjeta)]] as follows:
**Cycle 1: 840 mg IV once on day 1
**Cycle 2 onwards: 420 mg IV once on day 1
*[[Ado-trastuzumab emtansine (Kadcyla)]] 3.6 mg/kg IV once on day 1

'''21-day cycles'''

===References===
# '''MARIANNE:''' Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, Martin M, Pienkowski T, Pivot X, Burris H 3rd, Petersen JA, Stanzel S, Strasak A, Patre M, Ellis P. Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase III MARIANNE study. J Clin Oncol. 2017 Jan 10;35(2):141-148. Epub 2016 Nov 7. [http://ascopubs.org/doi/full/10.1200/JCO.2016.67.4887 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455677/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28056202 PubMed]

==TCH (Taxotere, Carboplatin) {{#subobject:cb6592|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
TCH: '''<u>T</u>'''axotere (Docetaxel), '''<u>C</u>'''arboplatin, '''<u>H</u>'''erceptin (Trastuzumab)

===Regimen {{#subobject:570bd5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/29/2/149.long Valero et al. 2011 (BCIRG 007)]
|style="background-color:#1a9851"|Phase III (E)
|[[#TH_.28Taxotere.29_3|TH]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1 
*[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1
*[[Trastuzumab (Herceptin)]] 4 mg/kg IV once on cycle 1 day 1, then 2 mg/kg IV once per week during chemotherapy

'''21-day cycle for 8 cycles'''
====Subsequent treatment====
*[[#Trastuzumab_monotherapy_4|Trastuzumab maintenance]]

===References===
# '''BCIRG 007:''' Valero V, Forbes J, Pegram MD, Pienkowski T, Eiermann W, von Minckwitz G, Roche H, Martin M, Crown J, Mackey JR, Fumoleau P, Rolski J, Mrsic-Krmpotic Z, Jagiello-Gruszfeld A, Riva A, Buyse M, Taupin H, Sauter G, Press MF, Slamon DJ. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol. 2011 Jan 10;29(2):149-56. Epub 2010 Nov 29. [http://jco.ascopubs.org/content/29/2/149.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21115860 PubMed]

==TH (Taxotere) {{#subobject:c99645|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
TH: '''<u>T</u>'''axotere (Docetaxel) & '''<u>H</u>'''erceptin (Trastuzumab)
<br>HT: '''<u>H</u>'''erceptin (Trastuzumab) & '''<u>T</u>'''axotere (Docetaxel)
<br>H+D: '''<u>H</u>'''erceptin (Trastuzumab) & '''<u>D</u>'''ocetaxel
===Variant #1, 35 mg/m<sup>2</sup> docetaxel, 3 out of 4 weeks {{#subobject:f2e79b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/20/7/1800.long Esteva et al. 2002]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/cncr.22885/abstract Burstein et al. 2007 (TRAVIOTA)]
|style="background-color:#1a9851"|Phase III (E)
|[[#VH_2|VH]]
|style="background-color:#fee08b"|Might have inferior TTP
|-
|}
''Esteva et al. 2002 described the day before the start of a cycle as "day 0," which is not the typical convention, so day -1 is being used instead.''
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 35 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1, 8, 15, '''given first'''
*[[Trastuzumab (Herceptin)]] '''given second''' as follows:
**Cycle 1: 4 mg/kg IV over 90 minutes once on day -1, then 2 mg/kg IV over 30 minutes once per day on days 8 & 15
**Cycle 2 onwards: 2 mg/kg IV over 30 minutes once per day on days 1, 8, 15

====Supportive medications====
*[[Dexamethasone (Decadron)]] 4 mg PO every 12 hours x 3 doses on cycles 1 & 2, starting the night before [[Docetaxel (Taxotere)]]. Patients who did not have "hypersensitivity reactions and no significant fluid retention during the first 8 weeks" received 4 mg PO twice per day on day 1 for at least the next two cycles. Patients who "remained free of fluid retention after 8 additional weeks" then received 4 mg PO once on day 1 prior to [[Docetaxel (Taxotere)]] in subsequent cycles.

'''28-day cycles'''

===Variant #2, 60 mg/m<sup>2</sup> q3wk docetaxel, weekly trastuzumab {{#subobject:8c2fd1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://link.springer.com/article/10.1007%2Fs10549-009-0498-7 Inoue et al. 2009 (JO17360)]
|style="background-color:#1a9851"|Phase III (C)
|H --> H + D
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Trastuzumab (Herceptin)]] 4 mg/kg IV once on day 1, then 2 mg/kg IV once per week

'''21-day cycles'''

===Variant #3, 75 mg/m<sup>2</sup> q3wk docetaxel, q3wk trastuzumab {{#subobject:d6d8da|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1113216 Baselga et al. 2011 (CLEOPATRA)]
|style="background-color:#1a9851"|Phase III (C)
|[[#THP_.28Taxotere.29_3|THP]]
|style="background-color:#d73027"|Inferior OS (*)
|-
|[http://jco.ascopubs.org/content/31/9/1157.long Hurvitz et al. 2013 (TDM4450g)]
|style="background-color:#1a9851"|Randomized Phase II (C)
|[[#T-DM1_monotherapy_3|T-DM1]]
|style="background-color:#fc8d59"|Seems to have inferior PFS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2014.56.9590 Gelmon et al. 2015 (NCIC CTG MA.31)]
|style="background-color:#1a9851"|Phase III (C)
|Docetaxel & Lapatinib
| style="background-color:#1a9850" |Superior PFS
|-
|rowspan=3|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455677/ Perez et al. 2016 (MARIANNE)]
|rowspan=3 style="background-color:#1a9851"|Phase III (C)
|1. [[#T-DM1_monotherapy_3|T-DM1]]
|style="background-color:#eeee01"|Non-inferior PFS
|-
|2. [[#Pertuzumab_.26_T-DM1|Pertuzumab & T-DM1]]
|style="background-color:#eeee01"|Non-inferior PFS
|-
|3. [[#TH_.28Taxol.29_3|TH (Taxol)]]
|style="background-color:#d3d3d3"|Not reported
|-
|}
''Note: Dose of docetaxel in Hurvitz et al. 2013 and MARIANNE was per investigator's discretion. CLEOPATRA has an unusual schedule with both medications being given on day 2 of cycle 1, due to this regimen being the control arm, in which patients in one arm received a placebo instead of pertuzumab on day 1. It is reasonable to assume that in practice, drugs in this regimen will be given on day 1 from the beginning. Efficacy for CLEOPATRA is based on the 2013 update.''
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 8 mg/kg IV once on day 2
**Cycle 2 onwards: 6 mg/kg IV once on day 1

'''21-day cycle for at least 6 cycles'''
====Subsequent treatment====
*CLEOPATRA: If it is decided to no longer administer docetaxel with this regimen, then patients could continue to receive [[#Trastuzumab_monotherapy_4|trastuzumab]] maintenance
*NCIC CTG MA.31: [[#Trastuzumab_monotherapy_4|Trastuzumab]] maintenance, after 8 cycles

===Variant #4, 100 mg/m<sup>2</sup> q3wk docetaxel, weekly trastuzumab {{#subobject:31786c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/23/19/4265.long Marty et al. 2005 (M77001)]
|style="background-color:#1a9851"|Randomized Phase II (E)
|[[Breast_cancer#Docetaxel_monotherapy|Docetaxel]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|[http://jco.ascopubs.org/content/29/2/149.long Valero et al. 2010 (BCIRG 007)]
|style="background-color:#1a9851"|Phase III (C)
|[[#TCH_.28Taxotere.2C_Carboplatin.29_2|TCH]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 100 mg/m<sup>2</sup> IV once on day 1
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 4 mg/kg IV over 90 minutes once on day 1, then 2 mg/kg IV over 30 minutes once per day on days 8 & 15
**Cycles 2 to 8: 2 mg/kg IV over 30 minutes once per day on days 1, 8, 15

====Supportive medications====
*[[Dexamethasone (Decadron)]] 8 mg (or equivalent) PO twice per day x 6 doses, starting the night before [[Docetaxel (Taxotere)]]
*"Antiemetic premedication was mandatory" (no additional details given).

'''21-day cycle for 6 cycles (M77001; see note) or 8 cycles (BCIRG 007)''' 
====Subsequent treatment====
*M77001: Patients could receive docetaxel beyond six cycles at the discretion of the investigator. Otherwise, patients proceeded to [[#Trastuzumab_monotherapy_4|trastuzumab maintenance]].
*BCIRG 007: [[#Trastuzumab_monotherapy_4|Trastuzumab maintenance]]

===Variant #5, 100 mg/m<sup>2</sup> q3wk docetaxel, q3wk trastuzumab {{#subobject:a951ac|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.30.8213 Andersson et al. 2010 (HERNATA)]
|style="background-color:#1a9851"|Phase III (C)
|[[#VH_2|VH]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://jco.ascopubs.org/content/31/9/1157.long Hurvitz et al. 2013 (TDM4450g)]
|style="background-color:#1a9851"|Randomized Phase II (C)
|[[#T-DM1_monotherapy_3|T-DM1]]
|style="background-color:#fc8d59"|Seems to have inferior PFS
|-
|[http://jco.ascopubs.org/content/31/14/1719.long Gianni et al. 2013 (AVAREL)]
|style="background-color:#1a9851"|Randomized Phase II (C)
|BTH
|style="background-color:#fee08b"|Might have inferior PFS
|-
|rowspan=3|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455677/ Perez et al. 2016 (MARIANNE)]
|rowspan=3 style="background-color:#1a9851"|Phase III (E)
|1. [[#T-DM1_monotherapy_3|T-DM1]]
|style="background-color:#eeee01"|Non-inferior PFS
|-
|2. [[#Pertuzumab_.26_T-DM1|Pertuzumab & T-DM1]]
|style="background-color:#eeee01"|Non-inferior PFS
|-
|3. [[#TH_.28Taxol.29_3|TH (Taxol)]]
|style="background-color:#d3d3d3"|Not reported
|-
|}
''Note: In HERNATA, the day of docetaxel and trastuzumab were reversed in cycle 1. Dose of docetaxel in Hurvitz et al. 2013 and MARIANNE was per investigator's discretion.''
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 100 mg/m<sup>2</sup> IV over 60 minutes once on day 1 (see note)
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 8 mg/kg IV over 90 minutes once on day 2 (see note)
**Cycle 2 onwards: 6 mg/kg IV over 30 minutes once on day 1

'''21-day cycles'''

===References===
# Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL, Hortobagyi GN. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2002 Apr 1;20(7):1800-8. [http://jco.ascopubs.org/content/20/7/1800.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11919237 PubMed]
# '''M77001:''' Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Antón A, Lluch A, Kennedy J, O'Byrne K, Conte P, Green M, Ward C, Mayne K, Extra JM. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005 Jul 1;23(19):4265-74. Epub 2005 May 23. [http://jco.ascopubs.org/content/23/19/4265.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15911866 PubMed]
# '''TRAVIOTA:''' Burstein HJ, Keshaviah A, Baron AD, Hart RD, Lambert-Falls R, Marcom PK, Gelman R, Winer EP. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer. 2007 Sep 1;110(5):965-72. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.22885/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17614302 PubMed]
# '''JO17360:''' Inoue K, Nakagami K, Mizutani M, Hozumi Y, Fujiwara Y, Masuda N, Tsukamoto F, Saito M, Miura S, Eguchi K, Shinkai T, Ando M, Watanabe T, Masuda N, Ohashi Y, Sano M, Noguchi S. Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group. Breast Cancer Res Treat. 2010 Jan;119(1):127-36. Epub 2009 Aug 19. [https://link.springer.com/article/10.1007%2Fs10549-009-0498-7 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19690954 PubMed]
# '''BCIRG 007:''' Valero V, Forbes J, Pegram MD, Pienkowski T, Eiermann W, von Minckwitz G, Roche H, Martin M, Crown J, Mackey JR, Fumoleau P, Rolski J, Mrsic-Krmpotic Z, Jagiello-Gruszfeld A, Riva A, Buyse M, Taupin H, Sauter G, Press MF, Slamon DJ. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol. 2011 Jan 10;29(2):149-56. Epub 2010 Nov 29. [http://jco.ascopubs.org/content/29/2/149.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21115860 PubMed]
# '''HERNATA:''' Andersson M, Lidbrink E, Bjerre K, Wist E, Enevoldsen K, Jensen AB, Karlsson P, Tange UB, Sørensen PG, Møller S, Bergh J, Langkjer ST. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol. 2011 Jan 20;29(3):264-71. Epub 2010 Dec 13. [http://ascopubs.org/doi/full/10.1200/JCO.2010.30.8213 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21149659 PubMed]
# '''CLEOPATRA:''' Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM; CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012 Jan 12;366(2):109-19. Epub 2011 Dec 7. [https://www.nejm.org/doi/full/10.1056/NEJMoa1113216 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22149875 PubMed]
## '''Update:''' Swain SM, Kim SB, Cortés J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Knott A, Clark E, Ross G, Benyunes MC, Baselga J. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013 May;14(6):461-71. Epub 2013 Apr 18. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70130-X/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4076842/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23602601 PubMed]
## '''Update:''' Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortés J; CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015 Feb 19;372(8):724-34. [https://www.nejm.org/doi/full/10.1056/NEJMoa1413513 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25693012 PubMed]
<!-- Presented at the European Multidisciplinary Cancer Congress, Stockholm, Sweden, September 23-27, 2011, and the European Society of Medical Oncology Congress, Milan, Italy, October 8–12, 2010. -->
# '''TDM4450g:''' Hurvitz SA, Dirix L, Kocsis J, Bianchi GV, Lu J, Vinholes J, Guardino E, Song C, Tong B, Ng V, Chu YW, Perez EA. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2013 Mar 20;31(9):1157-63. Epub 2013 Feb 4. Erratum in: J Clin Oncol. 2013 Aug 10;31(23):2977. [http://jco.ascopubs.org/content/31/9/1157.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23382472 PubMed]
<!-- Presented in part at the San Antonio Breast Cancer Symposium, San Antonio, TX, December 6-11, 2011. -->
# '''AVAREL:''' Gianni L, Romieu GH, Lichinitser M, Serrano SV, Mansutti M, Pivot X, Mariani P, Andre F, Chan A, Lipatov O, Chan S, Wardley A, Greil R, Moore N, Prot S, Pallaud C, Semiglazov V. AVEREL: a randomized phase III trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol. 2013 May 10;31(14):1719-25. Epub 2013 Apr 8. [http://jco.ascopubs.org/content/31/14/1719.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23569311 PubMed]
# '''NCIC CTG MA.31:''' Gelmon KA, Boyle FM, Kaufman B, Huntsman DG, Manikhas A, Di Leo A, Martin M, Schwartzberg LS, Lemieux J, Aparicio S, Shepherd LE, Dent S, Ellard SL, Tonkin K, Pritchard KI, Whelan TJ, Nomikos D, Nusch A, Coleman RE, Mukai H, Tjulandin S, Khasanov R, Rizel S, Connor AP, Santillana SL, Chapman JA, Parulekar WR. Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2-positive advanced breast cancer: final results of NCIC CTG MA.31. J Clin Oncol. 2015 May 10;33(14):1574-83. Epub 2015 Mar 16. [http://ascopubs.org/doi/full/10.1200/JCO.2014.56.9590 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25779558 PubMed]
# '''MARIANNE:''' Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, Martin M, Pienkowski T, Pivot X, Burris H 3rd, Petersen JA, Stanzel S, Strasak A, Patre M, Ellis P. Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase III MARIANNE study. J Clin Oncol. 2017 Jan 10;35(2):141-148. Epub 2016 Nov 7. [http://ascopubs.org/doi/full/10.1200/JCO.2016.67.4887 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455677/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28056202 PubMed]

==TH (Taxol) {{#subobject:aa22dd|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
TH: '''<u>T</u>'''axol (Paclitaxel), '''<u>H</u>'''erceptin (Trastuzumab)
<br>TP: '''<u>T</u>'''rastuzumab, '''<u>P</u>'''aclitaxel

===Variant #1, weekly paclitaxel (80 mg/m<sup>2</sup>) {{#subobject:2628d8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/cncr.22885/full Burstein et al. 2007 (TRAVIOTA)]
|style="background-color:#1a9851"|Phase III (E)
|[[#VH_2|VH]]
|style="background-color:#fee08b"|Might have inferior TTP
|-
|[http://jco.ascopubs.org/content/26/10/1642.long Seidman et al. 2008 (CALGB 9840)]
|style="background-color:#1a9851"|Phase III (E)
|TH, q3wk paclitaxel
|style="background-color:#1a9850"|Superior OS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433508/ Baselga et al. 2014 (STM01-102)]
|style="background-color:#1a9851"|Phase III (C)
|MTP
| style="background-color:#ffffbf" |Seems not superior
|-
|rowspan=3|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455677/ Perez et al. 2016 (MARIANNE)]
|rowspan=3 style="background-color:#1a9851"|Phase III (C)
|1. [[#T-DM1_monotherapy_3|T-DM1]]
|style="background-color:#eeee01"|Non-inferior PFS
|-
|2. [[#Pertuzumab_.26_T-DM1|Pertuzumab & T-DM1]]
|style="background-color:#eeee01"|Non-inferior PFS
|-
|3. [[#TH_.28Taxotere.29_3|TH (Taxotere)]]
|style="background-color:#d3d3d3"|Not reported
|-
|}
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV once per week
*[[Trastuzumab (Herceptin)]] 4 mg/kg IV once on day 1, then 2 mg/kg IV once per week

'''Continued indefinitely'''

===Variant #2, weekly paclitaxel (90 mg/m<sup>2</sup>) {{#subobject:2628d8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/19/10/2587.long Seidman et al. 2001]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 90 mg/m<sup>2</sup> IV once per week
*[[Trastuzumab (Herceptin)]] 4 mg/kg IV once on day 0 (the day before the first dose of paclitaxel), then 2 mg/kg IV once per week

'''Continued indefinitely'''

===Variant #3, paclitaxel 3 weeks out of 4, 6 cycles {{#subobject:812115|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2014.56.9590 Gelmon et al. 2015 (NCIC CTG MA.31)]
|style="background-color:#1a9851"|Phase III (C)
|Lapatinib & Paclitaxel
| style="background-color:#1a9850" |Superior PFS
|-
|}
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV once per day on days 1, 8, 15
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 4 mg/kg IV once on day 1, then 2 mg/kg IV once per day on days 8, 15, 22 
**Cycle 2 onwards: 2 mg/kg IV once per day on days 1, 8, 15, 22

'''28-day cycle for 6 cycles'''
====Subsequent treatment====
*[[#Trastuzumab_monotherapy_4|Trastuzumab]] maintenance

===Variant #4, paclitaxel 3 weeks out of 4, indefinite {{#subobject:bf7990|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00051-0/abstract Hurvitz et al. 2015 (BOLERO-1)]
|style="background-color:#1a9851"|Phase III (C)
|Everolimus, Paclitaxel, Trastuzumab
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://jamanetwork.com/journals/jamaoncology/fullarticle/2513249 Awada et al. 2016 (NEfERT-T)]
|style="background-color:#1a9851"|Phase III (C)
|Neratinib & Paclitaxel
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV once per day on days 1, 8, 15
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 4 mg/kg IV once on day 1, then 2 mg/kg IV once per day on days 8, 15, 22 
**Cycle 2 onwards: 2 mg/kg IV once per day on days 1, 8, 15, 22

'''28-day cycles'''

===Variant #5, q3wk paclitaxel {{#subobject:31e4b6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM200103153441101 Slamon et al. 2001]
|style="background-color:#1a9851"|Phase III (E)
|[[Breast_cancer#Paclitaxel_monotherapy.2C_q3wk|Paclitaxel]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|[http://jco.ascopubs.org/content/24/18/2786.long Robert et al. 2006]
|style="background-color:#1a9851"|Phase III (C)
|[[#TPC|TPC]]
|style="background-color:#fc8d59"|Seems to have inferior PFS
|-
|[http://jco.ascopubs.org/content/26/10/1642.long Seidman et al. 2008 (CALGB 9840)]
|style="background-color:#1a9851"|Phase III (C)
|TH, weekly paclitaxel (80 mg/m<sup>2</sup>)
|style="background-color:#d73027"|Inferior OS
|-
|}
====Chemotherapy====
*[[Paclitaxel (Taxol)]] as follows:
**Cycles 1 to 6: 175 mg/m<sup>2</sup> IV once on day 2 
**Cycle 7 onwards: continued at investigator's discretion
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 4 mg/kg IV once on day 1, then 2 mg/kg IV once per day on days 8 & 15 
**Cycle 2 onwards: 2 mg/kg IV once per day on days 1, 8, 15

'''21-day cycle for at least 6 cycles'''

===References===
# Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar 15;344(11):783-92. [https://www.nejm.org/doi/full/10.1056/NEJM200103153441101 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11248153 PubMed]
# Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, Panageas KS, Arroyo C, Valero V, Currie V, Gilewski T, Theodoulou M, Moynahan ME, Moasser M, Sklarin N, Dickler M, D'Andrea G, Cristofanilli M, Rivera E, Hortobagyi GN, Norton L, Hudis CA. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol. 2001 May 15;19(10):2587-95. [http://jco.ascopubs.org/content/19/10/2587.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11352950 PubMed]
# Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D, Raju R, Valentine E, Sayre R, Cobleigh M, Albain K, McCullough C, Fuchs L, Slamon D. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2006 Jun 20;24(18):2786-92. [http://jco.ascopubs.org/content/24/18/2786.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16782917 PubMed]
# '''TRAVIOTA:''' Burstein HJ, Keshaviah A, Baron AD, Hart RD, Lambert-Falls R, Marcom PK, Gelman R, Winer EP. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer. 2007 Sep 1;110(5):965-72. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.22885/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17614302 PubMed]
<!-- Presented at the 40th Annual Meeting of the American Society of Clinical Oncology, June 5-8, 2004, New Orleans, LA. -->
# '''CALGB 9840:''' Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis C. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 2008 Apr 1;26(10):1642-9. [http://jco.ascopubs.org/content/26/10/1642.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18375893 PubMed]
# '''STM01-102:''' Baselga J, Manikhas A, Cortés J, Llombart A, Roman L, Semiglazov VF, Byakhov M, Lokanatha D, Forenza S, Goldfarb RH, Matera J, Azarnia N, Hudis CA, Rozencweig M. Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. Ann Oncol. 2014 Mar;25(3):592-8. Epub 2014 Jan 8. [https://academic.oup.com/annonc/article/25/3/592/148877 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433508/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24401928 PubMed]
# '''NCIC CTG MA.31:''' Gelmon KA, Boyle FM, Kaufman B, Huntsman DG, Manikhas A, Di Leo A, Martin M, Schwartzberg LS, Lemieux J, Aparicio S, Shepherd LE, Dent S, Ellard SL, Tonkin K, Pritchard KI, Whelan TJ, Nomikos D, Nusch A, Coleman RE, Mukai H, Tjulandin S, Khasanov R, Rizel S, Connor AP, Santillana SL, Chapman JA, Parulekar WR. Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2-positive advanced breast cancer: final results of NCIC CTG MA.31. J Clin Oncol. 2015 May 10;33(14):1574-83. Epub 2015 Mar 16. [http://ascopubs.org/doi/full/10.1200/JCO.2014.56.9590 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25779558 PubMed]
# '''BOLERO-1:''' Hurvitz SA, Andre F, Jiang Z, Shao Z, Mano MS, Neciosup SP, Tseng LM, Zhang Q, Shen K, Liu D, Dreosti LM, Burris HA, Toi M, Buyse ME, Cabaribere D, Lindsay MA, Rao S, Pacaud LB, Taran T, Slamon D. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. Lancet Oncol. 2015 Jul;16(7):816-29. Epub 2015 Jun 16. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00051-0/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26092818 PubMed]
# '''MARIANNE:''' Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, Martin M, Pienkowski T, Pivot X, Burris H 3rd, Petersen JA, Stanzel S, Strasak A, Patre M, Ellis P. Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase III MARIANNE study. J Clin Oncol. 2017 Jan 10;35(2):141-148. Epub 2016 Nov 7. [http://ascopubs.org/doi/full/10.1200/JCO.2016.67.4887 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455677/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28056202 PubMed]
# '''NEfERT-T:''' Awada A, Colomer R, Inoue K, Bondarenko I, Badwe RA, Demetriou G, Lee SC, Mehta AO, Kim SB, Bachelot T, Goswami C, Deo S, Bose R, Wong A, Xu F, Yao B, Bryce R, Carey LA. neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer: The NEfERT-T randomized clinical trial. JAMA Oncol. 2016 Dec 1;2(12):1557-1564. [http://jamanetwork.com/journals/jamaoncology/fullarticle/2513249 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27078022 PubMed]

==THP (Taxotere) {{#subobject:938b69|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
THP: '''<u>T</u>'''axotere (Docetaxel), '''<u>H</u>'''erceptin (Trastuzumab), '''<u>P</u>'''ertuzumab
===Regimen {{#subobject:37f3dc|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1113216 Baselga et al. 2011 (CLEOPATRA)]
|style="background-color:#1a9851"|Phase III (E)
|[[#TH_.28Taxotere.29_3|Docetaxel & Trastuzumab]]
|style="background-color:#1a9850"|Superior OS (*)
|-
|}
''Efficacy is based on the 2013 update.''
====Chemotherapy====
*[[Docetaxel (Taxotere)]] as follows, '''given third''':
**Cycle 1: 75 mg/m<sup>2</sup> IV once on day 2
**Cycle 2 onwards: 75 mg/m<sup>2</sup> IV once on day 1
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 8 mg/kg IV over 90 minutes once on day 2
**Cycle 2 onwards: 6 mg/kg IV over 30 to 90 minutes once on day 1
*[[Pertuzumab (Perjeta)]] as follows:
**Cycle 1: 840 mg IV over 60 minutes once on day 1
**Cycle 2 onwards: 420 mg IV over 30 to 60 minutes once on day 1

'''21-day cycle for at least 6 cycles'''
====Subsequent treatment====
*If it is decided to no longer administer docetaxel, then patients could continue to receive [[#Pertuzumab_.26_Trastuzumab_2|pertuzumab & trastuzumab]] maintenance.

===References===
# '''CLEOPATRA:''' Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM; CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012 Jan 12;366(2):109-19. Epub 2011 Dec 7. [https://www.nejm.org/doi/full/10.1056/NEJMoa1113216 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22149875 PubMed]
## '''Update:''' Swain SM, Kim SB, Cortés J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Knott A, Clark E, Ross G, Benyunes MC, Baselga J. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013 May;14(6):461-71. Epub 2013 Apr 18. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70130-X/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4076842/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23602601 PubMed]
## '''Update:''' Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortés J; CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015 Feb 19;372(8):724-34. [https://www.nejm.org/doi/full/10.1056/NEJMoa1413513 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25693012 PubMed]

==TL (Taxol) {{#subobject:af5af0|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
TL: '''<u>T</u>'''axol (Paclitaxel) & '''<u>L</u>'''apatinib
===Regimen {{#subobject:6dda48|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2011.40.5241 Guan et al. 2013 (EGF104535)]
|style="background-color:#1a9851"|Phase III (E)
|[[Breast_cancer#Paclitaxel_monotherapy.2C_weekly_3|Paclitaxel]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|}
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV once per day on days 1, 8, 15
*[[Lapatinib (Tykerb)]] 1500 mg PO once per day

'''28-day cycles'''

===References===
<!-- Presented in part at the 33rd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12, 2010, and at the 36th Annual European Society of Medical Oncology Congress, Stockholm, Sweden, September 23-27, 2011. -->
# '''EGF104535:''' Guan Z, Xu B, DeSilvio ML, Shen Z, Arpornwirat W, Tong Z, Lorvidhaya V, Jiang Z, Yang J, Makhson A, Leung WL, Russo MW, Newstat B, Wang L, Chen G, Oliva C, Gomez H. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. J Clin Oncol. 2013 Jun 1;31(16):1947-53. Epub 2013 Mar 18. [http://ascopubs.org/doi/full/10.1200/JCO.2011.40.5241 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23509322 PubMed]
# '''NCIC CTG MA.31:''' Gelmon KA, Boyle FM, Kaufman B, Huntsman DG, Manikhas A, Di Leo A, Martin M, Schwartzberg LS, Lemieux J, Aparicio S, Shepherd LE, Dent S, Ellard SL, Tonkin K, Pritchard KI, Whelan TJ, Nomikos D, Nusch A, Coleman RE, Mukai H, Tjulandin S, Khasanov R, Rizel S, Connor AP, Santillana SL, Chapman JA, Parulekar WR. Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2-positive advanced breast cancer: final results of NCIC CTG MA.31. J Clin Oncol. 2015 May 10;33(14):1574-83. Epub 2015 Mar 16. [http://ascopubs.org/doi/full/10.1200/JCO.2014.56.9590 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25779558 PubMed]

==TPC {{#subobject:dc581d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
TPC: '''<u>T</u>'''rastuzumab, '''<u>P</u>'''aclitaxel, '''<u>C</u>'''arboplatin
<br>TCH: '''<u>T</u>'''axol (Paclitaxel), '''<u>C</u>'''arboplatin, '''<u>H</u>'''erceptin (Trastuzumab) 
===Variant #1, weekly {{#subobject:deacc5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.clinical-breast-cancer.com/article/S1526-8209(11)70461-X/abstract Perez et al. 2005 (NCCTG 983252)]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 4 mg/kg IV once on day 1, then 2 mg/kg IV once per day on days 8, 15, 22
**Cycles 2 to 6: 2 mg/kg IV once per day on days 1, 8, 15, 22
*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV once per day on days 1, 8, 15
*[[Carboplatin (Paraplatin)]] AUC 2 IV once per day on days 1, 8, 15

'''28-day cycle for 6 cycles'''
====Subsequent treatment====
*[[#Trastuzumab_monotherapy_4|Trastuzumab maintenance (weekly)]]

===Variant #2, weekly T, q3wk PC {{#subobject:573aed|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/24/18/2786.long Robert et al. 2006]
|style="background-color:#1a9851"|Phase III (E)
|[[#TH_.28Taxol.29_3|TP]]
|style="background-color:#91cf60"|Seems to have superior PFS
|-
|}
====Chemotherapy====
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 4 mg/kg IV once on day 1, then 2 mg/kg IV once per day on days 8 & 15 
**Cycle 2 onwards: 2 mg/kg IV once per day on days 1, 8, 15
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV once on day 2 
*[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 2

'''21-day cycle for at least 6 cycles'''
====Subsequent treatment====
*[[#Trastuzumab_monotherapy_4|Trastuzumab maintenance (weekly)]]

===Variant #3, q3wk {{#subobject:582fae|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.clinical-breast-cancer.com/article/S1526-8209(11)70461-X/abstract Perez et al. 2005 (NCCTG 983252)]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 8 mg/kg IV once on day 1 
**Cycles 2 to 8: 6 mg/kg IV once on day 1
*[[Paclitaxel (Taxol)]] 200 mg/m<sup>2</sup> IV once on day 1 
*[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1

'''21-day cycle for 8 cycles'''
====Subsequent treatment====
*[[#Trastuzumab_monotherapy_4|Trastuzumab maintenance (q3wk)]]
===References===
# '''NCCTG 983252:''' Perez EA, Suman VJ, Rowland KM, Ingle JN, Salim M, Loprinzi CL, Flynn PJ, Mailliard JA, Kardinal CG, Krook JE, Thrower AR, Visscher DW, Jenkins RB. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer. 2005 Dec;6(5):425-32. [http://www.clinical-breast-cancer.com/article/S1526-8209(11)70461-X/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16381626 PubMed]
# Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D, Raju R, Valentine E, Sayre R, Cobleigh M, Albain K, McCullough C, Fuchs L, Slamon D. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2006 Jun 20;24(18):2786-92. [http://jco.ascopubs.org/content/24/18/2786.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16782917 PubMed]

==T-DM1 monotherapy {{#subobject:d320be|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
T-DM1: '''<u>T</u>'''rastuzumab-'''<u>DM1</u>''' (ado-Trastuzumab emtansine)
===Example orders===
*[[Example orders for Ado-trastuzumab emtansine (Kadcyla) in breast cancer]]

===Regimen {{#subobject:63b7de|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/31/9/1157.long Hurvitz et al. 2013]
|style="background-color:#1a9851"|Randomized Phase II (E)
|[[#TH_.28Taxotere.29_3|TH]]
|style="background-color:#91cf60"|Seems to have superior PFS
|-
|rowspan=2|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455677/ Perez et al. 2016 (MARIANNE)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. T-DM1 & Pertuzumab
|style="background-color:#eeee01"|Non-inferior PFS
|-
|2. [[#TH_.28Taxotere.29_3|TH (Taxotere)]]<br> 3. [[#TH_.28Taxol.29_3|TH (Taxol)]]
|style="background-color:#eeee01"|Non-inferior PFS
|-
|}
====Chemotherapy====
*[[Ado-trastuzumab emtansine (Kadcyla)]] 3.6 mg/kg IV once on day 1

'''21-day cycles'''

===References===
<!-- Presented at the European Multidisciplinary Cancer Congress, Stockholm, Sweden, September 23-27, 2011, and the European Society of Medical Oncology Congress, Milan, Italy, October 8–12, 2010. -->
# Hurvitz SA, Dirix L, Kocsis J, Bianchi GV, Lu J, Vinholes J, Guardino E, Song C, Tong B, Ng V, Chu YW, Perez EA. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2013 Mar 20;31(9):1157-63. Epub 2013 Feb 4. Erratum in: J Clin Oncol. 2013 Aug 10;31(23):2977. [http://jco.ascopubs.org/content/31/9/1157.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23382472 PubMed]
# '''MARIANNE:''' Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, Martin M, Pienkowski T, Pivot X, Burris H 3rd, Petersen JA, Stanzel S, Strasak A, Patre M, Ellis P. Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase III MARIANNE study. J Clin Oncol. 2017 Jan 10;35(2):141-148. Epub 2016 Nov 7. [http://ascopubs.org/doi/full/10.1200/JCO.2016.67.4887 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455677/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28056202 PubMed]

==Trastuzumab monotherapy {{#subobject:9dedb2|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:9be86b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/annonc/article/28/2/305/2725474 Pagani et al. 2017 (SAKK 22/99)]
|style="background-color:#1a9851"|Phase III (C)
|Chemotherapy & Trastuzumab
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Trastuzumab (Herceptin)]]
===References===
# '''SAKK 22/99:''' Pagani O, Klingbiel D, Ruhstaller T, Nolè F, Eppenberger S, Oehlschlegel C, Bernhard J, Brauchli P, Hess D, Mamot C, Munzone E, Pestalozzi B, Rabaglio M, Aebi S, Ribi K, Rochlitz C, Rothgiesser K, Thürlimann B, von Moos R, Zaman K, Goldhirsch A; Swiss Group for Clinical Cancer Research (SAKK). Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99. Ann Oncol. 2017 Feb 1;28(2):305-312. [https://academic.oup.com/annonc/article/28/2/305/2725474 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27998961 PubMed]

==VH {{#subobject:59edc1|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
VH: '''<u>V</u>'''inorelbine & '''<u>H</u>'''erceptin (Trastuzumab)
===Variant #1, vinorelbine 25 mg/m<sup>2</sup> {{#subobject:947c3a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/cncr.22885/abstract Burstein et al. 2007 (TRAVIOTA)]
|style="background-color:#1a9851"|Phase III (E)
|[[#TH_.28Taxotere.29_3|TH (Taxotere)]]<br> [[#TH_.28Taxol.29_3|TH (Taxol)]]
|style="background-color:#d9ef8b"|Might have superior TTP
|-
|}
====Chemotherapy====
*[[Vinorelbine (Navelbine)]] 25 mg/m<sup>2</sup> IV once per week
*[[Trastuzumab (Herceptin)]] 4 mg/kg IV once on day 1, then 2 mg/kg IV once per week

'''Given indefinitely'''

===Variant #2, vinorelbine 30 mg/m<sup>2</sup>, 2 out of 3 weeks {{#subobject:fac964|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.30.8213 Andersson et al. 2010 (HERNATA)]
|style="background-color:#1a9851"|Phase III (E)
|[[#TH_.28Taxotere.29_3|TH (Taxotere)]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Vinorelbine (Navelbine)]] 30 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 8 mg/kg IV over 90 minutes once on day 1
**Cycle 2 onwards: 6 mg/kg IV over 30 minutes once on day 1

'''21-day cycles'''

===Variant #3, vinorelbine 35 mg/m<sup>2</sup>, 2 out of 3 weeks {{#subobject:a6dae9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.30.8213 Andersson et al. 2010 (HERNATA)]
|style="background-color:#1a9851"|Phase III (E)
|[[#TH_.28Taxotere.29_3|TH (Taxotere)]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Vinorelbine (Navelbine)]] 35 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 8 mg/kg IV over 90 minutes once on day 1
**Cycle 2 onwards: 6 mg/kg IV over 30 minutes once on day 1

'''21-day cycles'''

===References===
# '''TRAVIOTA:''' Burstein HJ, Keshaviah A, Baron AD, Hart RD, Lambert-Falls R, Marcom PK, Gelman R, Winer EP. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer. 2007 Sep 1;110(5):965-72. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.22885/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17614302 PubMed]
# '''HERNATA:''' Andersson M, Lidbrink E, Bjerre K, Wist E, Enevoldsen K, Jensen AB, Karlsson P, Tange UB, Sørensen PG, Møller S, Bergh J, Langkjer ST. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol. 2011 Jan 20;29(3):264-71. Epub 2010 Dec 13. [http://ascopubs.org/doi/full/10.1200/JCO.2010.30.8213 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21149659 PubMed]

=Metastatic or unresectable disease, subsequent lines=
==Capecitabine & Lapatinib {{#subobject:5474dd|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:6d0733|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa064320 Geyer et al. 2006 (EGF100151)]
|style="background-color:#1a9851"|Phase III (E)
|[[Breast_cancer#Capecitabine_monotherapy_3|Capecitabine]]
|style="background-color:#1a9850"|Superior TTP
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125250/ Verma et al. 2012 (EMILIA)]
|style="background-color:#1a9851"|Phase III (C)
|[[#T-DM1_monotherapy_4|T-DM1]]
|style="background-color:#d73027"|Inferior OS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2014.57.1794 Pivot et al. 2015 (CEREBEL)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Capecitabine_.26_Trastuzumab_2|Capecitabine & Trastuzumab]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: the primary endpoint of CEREBEL was incidence of CNS as site of first relapse; this was very low in both arms, with no statistically significant difference.''
====Chemotherapy====
*[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14
*[[Lapatinib (Tykerb)]] 1250 mg PO once per day

'''21-day cycles'''

===References===
# '''EGF100151:''' Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006 Dec 28;355(26):2733-43. [https://www.nejm.org/doi/full/10.1056/NEJMoa064320 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17192538 PubMed]
## '''Update:''' Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, Chan S, Jagiello-Gruszfeld A, Kaufman B, Crown J, Chan A, Campone M, Viens P, Davidson N, Gorbounova V, Raats JI, Skarlos D, Newstat B, Roychowdhury D, Paoletti P, Oliva C, Rubin S, Stein S, Geyer CE. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008 Dec;112(3):533-43. [http://link.springer.com/article/10.1007%2Fs10549-007-9885-0 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18188694 PubMed]
## '''Update:''' Cameron D, Casey M, Oliva C, Newstat B, Imwalle B, Geyer CE. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist. 2010;15(9):924-34. [http://theoncologist.alphamedpress.org/content/15/9/924.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228041/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20736298 PubMed]
# '''EMILIA:''' Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K; EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012 Nov 8;367(19):1783-91. Epub 2012 Oct 1. Erratum in: N Engl J Med. 2013 Jun 20;368(25):2442. [https://www.nejm.org/doi/full/10.1056/NEJMoa1209124 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125250/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23020162 PubMed]
## '''Update:''' Diéras V, Miles D, Verma S, Pegram M, Welslau M, Baselga J, Krop IE, Blackwell K, Hoersch S, Xu J, Green M, Gianni L. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2017 Jun;18(6):732-742. Epub 2017 May 16. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30312-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5531181/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28526536 PubMed]
# '''CEREBEL:''' Pivot X, Manikhas A, Żurawski B, Chmielowska E, Karaszewska B, Allerton R, Chan S, Fabi A, Bidoli P, Gori S, Ciruelos E, Dank M, Hornyak L, Margolin S, Nusch A, Parikh R, Nagi F, DeSilvio M, Santillana S, Swaby RF, Semiglazov V. CEREBEL (EGF111438): A phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2015 May 10;33(14):1564-73. Epub 2015 Jan 20. [http://ascopubs.org/doi/full/10.1200/JCO.2014.57.1794 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25605838 PubMed]

==Capecitabine & Neratinib {{#subobject:01baec|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:3a0475|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2014.56.3809 Saura et al. 2014]
|style="background-color:#91cf61"|Phase I/II
| style="background-color:#bfd3e6" |ORR: 64%
|-
|}
''Note: this is the MTD dose from the phase II portion.''
====Chemotherapy====
*[[Capecitabine (Xeloda)]] 750 mg/m<sup>2</sup> PO twice per day on days 1 to 14
*[[Neratinib (Nerlynx)]] 240 mg PO once per day

'''21-day cycles'''

===References===
# Saura C, Garcia-Saenz JA, Xu B, Harb W, Moroose R, Pluard T, Cortés J, Kiger C, Germa C, Wang K, Martin M, Baselga J, Kim SB. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2014 Nov 10;32(32):3626-33. Epub 2014 Oct 6. [http://ascopubs.org/doi/full/10.1200/JCO.2014.56.3809 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25287822 PubMed]

==Capecitabine, Pertuzumab, Trastuzumab {{#subobject:fa074d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:b7d240|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2016.70.6267 Urruticoechea et al. 2017 (PHEREXA)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Capecitabine_.26_Trastuzumab_2|Capecitabine & Trastuzumab]]
|style="background-color:#d9ef8b"|Might have superior PFS
|-
|}
====Chemotherapy====
*[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14
*[[Pertuzumab (Perjeta)]] as follows:
**Cycle 1: 840 mg IV once on day 1
**Cycle 2 onwards: 420 mg IV once on day 1
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 8 mg/kg IV once on day 1
**Cycle 2 onwards: 6 mg/kg IV once on day 1

'''21-day cycles'''

===References===
# Urruticoechea A, Rizwanullah M, Im SA, Ruiz ACS, Láng I, Tomasello G, Douthwaite H, Badovinac Crnjevic T, Heeson S, Eng-Wong J, Muñoz M. Randomized phase III trial of trastuzumab plus capecitabine with or without pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who experienced disease progression during or after trastuzumab-based therapy. J Clin Oncol. 2017 Sep 10;35(26):3030-3038. Epub 2017 Apr 24. [http://ascopubs.org/doi/full/10.1200/JCO.2016.70.6267 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28437161 PubMed]

==Capecitabine & Trastuzumab {{#subobject:8d0dd5|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
XH: '''<u>X</u>'''eloda (Capecitabine) & '''<u>H</u>'''erceptin
===Variant #1 {{#subobject:663bcc|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/25/25/3853.long Bartsch et al. 2007]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|ORR: 20%
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2014.57.1794 Pivot et al. 2015 (CEREBEL)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Capecitabine_.26_Lapatinib_2|Capecitabine & Lapatanib]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2016.70.6267 Urruticoechea et al. 2017 (PHEREXA)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Capecitabine.2C_Pertuzumab.2C_Trastuzumab|Capecitabine, Pertuzumab, Trastuzumab]]
|style="background-color:#fee08b"|Might have inferior PFS
|-
|}
''Note: the only difference between this and variant #2 is the use of a loading dose of trastuzumab. The primary endpoint of CEREBEL was incidence of CNS as site of first relapse; this was very low in both arms, with no statistically significant difference.''
====Chemotherapy====
*[[Capecitabine (Xeloda)]] 1250 mg/m<sup>2</sup> PO twice per day on days 1 to 14
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 8 mg/kg IV once on day 1
**Cycle 2 onwards: 6 mg/kg IV once on day 1

'''21-day cycles'''

===Variant #2 {{#subobject:e38ff|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/27/12/1999.long von Minckwitz et al. 2009 (GBG 26/BIG 3-05)]
|style="background-color:#1a9851"|Phase III (E)
|[[Breast_cancer#Capecitabine_monotherapy_3|Capecitabine]]
|style="background-color:#91cf60"|Seems to have superior TTP
|-
|}
''This is a continuation of trastuzumab so there is no loading dose.''
====Chemotherapy====
*[[Capecitabine (Xeloda)]] 1250 mg/m<sup>2</sup> PO twice per day on days 1 to 14
*[[Trastuzumab (Herceptin)]] 6 mg/kg IV once on day 1

'''21-day cycles'''

===References===
# Bartsch R, Wenzel C, Altorjai G, Pluschnig U, Rudas M, Mader RM, Gnant M, Zielinski CC, Steger GG. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol. 2007 Sep 1;25(25):3853-8. Epub 2007 Aug 6. [http://jco.ascopubs.org/content/25/25/3853.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17679724 PubMed]
# '''GBG 26/BIG 3-05:''' von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, Maartense E, Zielinski C, Kaufmann M, Bauer W, Baumann KH, Clemens MR, Duerr R, Uleer C, Andersson M, Stein RC, Nekljudova V, Loibl S. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol. 2009 Apr 20;27(12):1999-2006. Epub 2009 Mar 16. [http://jco.ascopubs.org/content/27/12/1999.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19289619 PubMed]
## '''Update:''' von Minckwitz G, Schwedler K, Schmidt M, Barinoff J, Mundhenke C, Cufer T, Maartense E, de Jongh FE, Baumann KH, Bischoff J, Harbeck N, Lück HJ, Maass N, Zielinski C, Andersson M, Stein RC, Nekljudova V, Loibl S; GBG 26/BIG 03-05 study group and participating investigators. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer. 2011 Oct;47(15):2273-81. Epub 2011 Jul 7. [https://www.ejcancer.com/article/S0959-8049(11)00425-4/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21741829 PubMed]
# '''CEREBEL:''' Pivot X, Manikhas A, Żurawski B, Chmielowska E, Karaszewska B, Allerton R, Chan S, Fabi A, Bidoli P, Gori S, Ciruelos E, Dank M, Hornyak L, Margolin S, Nusch A, Parikh R, Nagi F, DeSilvio M, Santillana S, Swaby RF, Semiglazov V. CEREBEL (EGF111438): A phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2015 May 10;33(14):1564-73. Epub 2015 Jan 20. [http://ascopubs.org/doi/full/10.1200/JCO.2014.57.1794 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25605838 PubMed]
# '''PHEREXA:''' Urruticoechea A, Rizwanullah M, Im SA, Ruiz ACS, Láng I, Tomasello G, Douthwaite H, Badovinac Crnjevic T, Heeson S, Eng-Wong J, Muñoz M. Randomized phase III trial of trastuzumab plus capecitabine with or without pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who experienced disease progression during or after trastuzumab-based therapy. J Clin Oncol. 2017 Sep 10;35(26):3030-3038. Epub 2017 Apr 24. [http://ascopubs.org/doi/full/10.1200/JCO.2016.70.6267 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28437161 PubMed]

==Lapatinib & Trastuzumab {{#subobject:9be4d2|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:e892bb|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/28/7/1124.long Blackwell et al. 2010 (EGF104900)]
|style="background-color:#1a9851"|Phase III (E)
|Lapatinib
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
====Chemotherapy====
*[[Lapatinib (Tykerb)]] 1000 mg PO once per day
*[[Trastuzumab (Herceptin)]] 4 mg/kg IV once on day 1, then 2 mg/kg IV once per week

'''Given indefinitely'''

===References===
<!-- Presented in part at the 44th Annual Meeting of the American Society of Clinical Oncology, May 30-June 3, 2008, Chicago, IL, and the 33rd Annual Meeting of the European Society for Medical Oncology, September 12-16, 2008, Stockholm, Sweden. -->
# Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, Ellis C, Casey M, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010 Mar 1;28(7):1124-30. Epub 2010 Feb 1. [http://jco.ascopubs.org/content/28/7/1124.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/20124187 PubMed]
## '''Update:''' Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, Ellis C, Florance A, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol. 2012 Jul 20;30(21):2585-92. Epub 2012 Jun 11. [http://jco.ascopubs.org/content/30/21/2585.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22689807 PubMed]

==Pertuzumab & Trastuzumab {{#subobject:b1d7b1|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, q3wk trastuzumab {{#subobject:4f5a4d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979216/ Baselga et al. 2010]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Pertuzumab (Perjeta)]] as follows, '''given second''':
**Cycle 1: 840 mg IV once on day 2
**Cycle 2 onwards: 420 mg IV once on day 1
*[[Trastuzumab (Herceptin)]] as follows:
**Loading dose: 8 mg/kg IV once on day -28 (that is, 28 days before the start of cycle 1)
**Cycle 1 onwards: 6 mg/kg IV once on day 1, '''given first'''

'''21-day cycle for 8 cycles'''

''Treatment can be continued if there is no progressive disease.''

===Variant #2, weekly trastuzumab {{#subobject:ecb953|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979216/ Baselga et al. 2010]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
Loading dose:
*[[Trastuzumab (Herceptin)]] 4 mg/kg IV once on day -28 (that is, 28 days before the start of cycle 1)

Cycles 1 to 8:
*[[Pertuzumab (Perjeta)]] as follows, '''given second''':
**Cycle 1: 840 mg IV once on day 2
**Cycle 2 onwards: 420 mg IV once on day 1
*[[Trastuzumab (Herceptin)]] 2 mg/kg IV once per day on days 1, 8, 15, '''given first'''

'''21-day cycle for 8 cycles'''; treatment can be continued if there is no progressive disease

===References===
# Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, Bianchi G, Cortes J, McNally VA, Ross GA, Fumoleau P, Gianni L. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol. 2010 Mar 1;28(7):1138-44. Epub 2010 Feb 1. [http://jco.ascopubs.org/content/28/7/1138.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979216/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20124182 PubMed]

==T-DM1 monotherapy {{#subobject:d260e0|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
T-DM1: '''<u>T</u>'''rastuzumab-'''<u>DM1</u>''' (ado-Trastuzumab emtansine)
===Example orders===
*[[Example orders for Ado-trastuzumab emtansine (Kadcyla) in breast cancer]]

===Regimen {{#subobject:d42e82|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125250/ Verma et al. 2012 (EMILIA)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Capecitabine_.26_Lapatinib_2|Capecitabine & Lapatinib]]
|style="background-color:#1a9850"|Superior OS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70178-0/fulltext Krop et al. 2014 (TH3RESA)]
|style="background-color:#1a9851"|Phase III (E)
|Physician's choice
|style="background-color:#1a9850"|Superior OS (*)
|-
|}
''Note: reported efficacy for '''TH3RESA''' is based on the 2017 update.''
====Chemotherapy====
*[[Ado-trastuzumab emtansine (Kadcyla)]] 3.6 mg/kg IV once on day 1

'''21-day cycles'''

===References===
# '''EMILIA:''' Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K; EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012 Nov 8;367(19):1783-91. Epub 2012 Oct 1. Erratum in: N Engl J Med. 2013 Jun 20;368(25):2442. [https://www.nejm.org/doi/full/10.1056/NEJMoa1209124 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125250/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23020162 PubMed]
## '''Update:''' Diéras V, Miles D, Verma S, Pegram M, Welslau M, Baselga J, Krop IE, Blackwell K, Hoersch S, Xu J, Green M, Gianni L. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2017 Jun;18(6):732-742. Epub 2017 May 16. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30312-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5531181/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28526536 PubMed]
# '''TH3RESA:''' Krop IE, Kim SB, González-Martín A, LoRusso PM, Ferrero JM, Smitt M, Yu R, Leung AC, Wildiers H; TH3RESA study collaborators. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014 Jun;15(7):689-99. Epub 2014 May 2. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70178-0/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24793816 PubMed]
## '''Update:''' Krop IE, Kim SB, Martin AG, LoRusso PM, Ferrero JM, Badovinac-Crnjevic T, Hoersch S, Smitt M, Wildiers H. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 2017 Jun;18(6):743-754. Epub 2017 May 16. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30313-3/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28526538 PubMed]

==VH {{#subobject:932de7|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
VH: '''<u>V</u>'''inorelbine & '''<u>H</u>'''erceptin (Trastuzumab)
===Regimen {{#subobject:55cd14|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70138-X/abstract André et al. 2014 (BOLERO-3)]
|style="background-color:#1a9851"|Phase III (C)
|Everolimus, Trastuzumab, Vinorelbine
|style="background-color:#d73027"|Inferior PFS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00540-9/fulltext Harbeck et al. 2016 (LUX-Breast 1)]
|style="background-color:#1a9851"|Phase III (C)
|Afatinib & Vinorelbine
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Vinorelbine (Navelbine)]] 25 mg/m<sup>2</sup> IV once per week
*[[Trastuzumab (Herceptin)]] 4 mg/kg IV once on day 1, then 2 mg/kg IV once per week

'''Given indefinitely'''

===References===
# '''BOLERO-3:''' André F, O'Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, Masuda N, Wilks S, Arena F, Isaacs C, Yap YS, Papai Z, Lang I, Armstrong A, Lerzo G, White M, Shen K, Litton J, Chen D, Zhang Y, Ali S, Taran T, Gianni L. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014 May;15(6):580-91. Epub 2014 Apr 14. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70138-X/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24742739 PubMed]
# '''LUX-Breast 1:''' Harbeck N, Huang CS, Hurvitz S, Yeh DC, Shao Z, Im SA, Jung KH, Shen K, Ro J, Jassem J, Zhang Q, Im YH, Wojtukiewicz M, Sun Q, Chen SC, Goeldner RG, Uttenreuther-Fischer M, Xu B, Piccart-Gebhart M; LUX-Breast 1 study group. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. Lancet Oncol. 2016 Mar;17(3):357-66. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00540-9/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26822398 PubMed]

=Maintenance for metastatic or unresectable disease=
==Pertuzumab & Trastuzumab {{#subobject:75e894|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:ecd17f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1113216 Baselga et al. 2011 (CLEOPATRA)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
====Preceding treatment====
*[[#THP_.28Taxotere.29_3|THP (Taxotere)]] for at least 6 cycles

====Chemotherapy====
*[[Pertuzumab (Perjeta)]] 420 mg IV once on day 1
*[[Trastuzumab (Herceptin)]] 6 mg/kg IV once on day 1

'''21-day cycles'''

===References===
# '''CLEOPATRA:''' Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM; CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012 Jan 12;366(2):109-19. Epub 2011 Dec 7. [https://www.nejm.org/doi/full/10.1056/NEJMoa1113216 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22149875 PubMed]
## '''Update:''' Swain SM, Kim SB, Cortés J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Knott A, Clark E, Ross G, Benyunes MC, Baselga J. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013 May;14(6):461-71. Epub 2013 Apr 18. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70130-X/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4076842/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23602601 PubMed]
## '''Update:''' Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortés J; CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015 Feb 19;372(8):724-34. [https://www.nejm.org/doi/full/10.1056/NEJMoa1413513 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25693012 PubMed]

==Trastuzumab monotherapy {{#subobject:c88145|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, q3wk dosing {{#subobject:da43ac|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.clinical-breast-cancer.com/article/S1526-8209(11)70461-X/abstract Perez et al. 2005 (NCCTG 983252)]
| style="background-color:#91cf61" |Phase II
|-
|[http://jco.ascopubs.org/content/29/2/149.long Valero et al. 2010 (BCIRG 007)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1113216 Baselga et al. 2011 (CLEOPATRA)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2014.56.9590 Gelmon et al. 2015 (NCIC CTG MA.31)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
====Preceding treatment====
*NCCTG 983252: [[#TPC|TPC (q3wk)]] x 8
*BCIRG 0007: [[#TH_.28Taxotere.29_3|TH (Taxotere)]] x 8 versus [[#TCH_.28Taxotere.2C_Carboplatin.29_2|TCH (Taxotere)]] x 8
*CLEOPATRA: [[#TH_.28Taxotere.29_3|TH (Taxotere)]]
*NCIC CTG MA.31: [[#TH_.28Taxol.29_3|TH (Taxol)]] x 6 or [[#TH_.28Taxotere.29_3|TH (Taxotere)]] x 8

====Chemotherapy====
*[[Trastuzumab (Herceptin)]] 6 mg/kg IV once on day 1

'''21-day cycles'''

===Variant #2, weekly dosing {{#subobject:1ac92c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/23/19/4265.long Marty et al. 2005 (M77001)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|[http://www.clinical-breast-cancer.com/article/S1526-8209(11)70461-X/abstract Perez et al. 2005 (NCCTG 983252)]
| style="background-color:#91cf61" |Phase II
|-
|[http://jco.ascopubs.org/content/24/18/2786.long Robert et al. 2006]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
====Preceding treatment====
*M77001: [[#TH_.28Taxotere.29_3|TH (Taxotere)]] for at least 6 cycles
*NCCTG 983252: [[#TPC|TPC (weekly)]] x 6
*Robert et al. 2006: [[#TH_.28Taxol.29_3|TP]] x 6 versus [[#TPC|TPC]] x 6
====Chemotherapy====
*[[Trastuzumab (Herceptin)]] 2 mg/kg IV once per week

'''Given indefinitely'''

===References===
# '''M77001:''' Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Antón A, Lluch A, Kennedy J, O'Byrne K, Conte P, Green M, Ward C, Mayne K, Extra JM. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005 Jul 1;23(19):4265-74. Epub 2005 May 23. [http://jco.ascopubs.org/content/23/19/4265.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15911866 PubMed]
# '''NCCTG 983252:''' Perez EA, Suman VJ, Rowland KM, Ingle JN, Salim M, Loprinzi CL, Flynn PJ, Mailliard JA, Kardinal CG, Krook JE, Thrower AR, Visscher DW, Jenkins RB. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer. 2005 Dec;6(5):425-32. [http://www.clinical-breast-cancer.com/article/S1526-8209(11)70461-X/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16381626 PubMed]
# Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D, Raju R, Valentine E, Sayre R, Cobleigh M, Albain K, McCullough C, Fuchs L, Slamon D. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2006 Jun 20;24(18):2786-92. [http://jco.ascopubs.org/content/24/18/2786.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16782917 PubMed]
# '''BCIRG 007:''' Valero V, Forbes J, Pegram MD, Pienkowski T, Eiermann W, von Minckwitz G, Roche H, Martin M, Crown J, Mackey JR, Fumoleau P, Rolski J, Mrsic-Krmpotic Z, Jagiello-Gruszfeld A, Riva A, Buyse M, Taupin H, Sauter G, Press MF, Slamon DJ. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol. 2011 Jan 10;29(2):149-56. Epub 2010 Nov 29. [http://jco.ascopubs.org/content/29/2/149.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21115860 PubMed]
# '''CLEOPATRA:''' Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM; CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012 Jan 12;366(2):109-19. Epub 2011 Dec 7. [https://www.nejm.org/doi/full/10.1056/NEJMoa1113216 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22149875 PubMed]
## '''Update:''' Swain SM, Kim SB, Cortés J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Knott A, Clark E, Ross G, Benyunes MC, Baselga J. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013 May;14(6):461-71. Epub 2013 Apr 18. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70130-X/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4076842/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23602601 PubMed]
## '''Update:''' Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortés J; CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015 Feb 19;372(8):724-34. [https://www.nejm.org/doi/full/10.1056/NEJMoa1413513 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25693012 PubMed]
# '''NCIC CTG MA.31:''' Gelmon KA, Boyle FM, Kaufman B, Huntsman DG, Manikhas A, Di Leo A, Martin M, Schwartzberg LS, Lemieux J, Aparicio S, Shepherd LE, Dent S, Ellard SL, Tonkin K, Pritchard KI, Whelan TJ, Nomikos D, Nusch A, Coleman RE, Mukai H, Tjulandin S, Khasanov R, Rizel S, Connor AP, Santillana SL, Chapman JA, Parulekar WR. Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2-positive advanced breast cancer: final results of NCIC CTG MA.31. J Clin Oncol. 2015 May 10;33(14):1574-83. Epub 2015 Mar 16. [http://ascopubs.org/doi/full/10.1200/JCO.2014.56.9590 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25779558 PubMed]

=Additional resources=
*[http://www.cancer.gov/bcrisktool/ Gail model Breast Cancer Risk Assessment Tool]
**[[Gail model breast cancer risk factors]]
*[[Breast cancer BRCA1/BRCA2 genetic testing]]
*[http://www.adjuvantonline.com/index.jsp/ Adjuvant! Online (requires login)]
*[http://www.mycancergenome.org/content/disease/breast-cancer/ My Cancer Genome]

=Patient information=
*[http://www.lakeviewhealth.com/alcohol-increase-breast-cancer-risk-factors-infographic.php Alcohol and risk of breast cancer infographic]

[[Category:Breast cancer regimens]]
[[Category:Biomarker-specific pages]]
[[Category:Breast cancers]]
